


December 2024 Office of Chemical Safety and Pollution Prevention

Draft Consumer and Indoor Dust Exposure Assessment for Dicyclohexyl Phthalate (DCHP)

Technical Support Document for the Draft Risk Evaluation

CASRN 84-61-7



- 1/

December 2024

24 TABLE OF CONTENTS

25	SUMMARY	5
26	1 INTRODUCTION	6
27	2 CONSUMER EXPOSURE APPROACH AND METHODOLOGY	8
28 29 30 31 32 33 34 35 36 37 38 39 40	 2.1 Products and Articles with DCHP Content	
41 42	 2.4 Key Parameters for Intermediate Exposures	
43 44 45 46	 3.1 Acute Dose Rate Results, Data, Patterns, and Conclusions	36 37 40
47	4.1 Indoor Dust Monitoring Data	
48 49	 4.2 Indoor Dust Monitoring Ingestion Dose Results	
50 51 52 53 54 55 56 57 58	 5.1 Consumer Exposure Analysis Weight of Scientific Evidence	43 47 48 48 49 49 50 50
59 60 61	 5.2.1.3 Uncertainties for Dust Ingestion Rates	51 51 52
62	6 CONCLUSION AND STEPS TOWARDS RISK CHARACTERIZATION	
63	7 REFERENCES	
64	Appendix A ACUTE, CHRONIC, AND INTERMEDIATE DOSE RATE EQUATIONS	
65	A.1 Acute Dose Rate	59

66	A.2	Non-cancer Chronic Dose	
67	A.3	Intermediate Average Daily Dose	
68		Dermal Absorption Dose Modeling for Acute and Chronic Exposures	
69			

70 LIST OF TABLES

71	Table 1-1. Consumer Conditions of Use Table	7
72	Table 2-1. Summary of Consumer COUs, Exposure Scenarios, and Exposure Routes	13
73	Table 2-2. COUs and Products or Articles Without a Quantitative Assessment	16
74	Table 2-3. CEM 3.2 Model Codes and Descriptions	20
75	Table 2-4. Crosswalk of COU Subcategories, CEM 3.2 Scenarios, and Relevant CEM 3.2 Models	
76	Used for Consumer Modeling	20
77	Table 2-5. Summary of Key Parameters for Inhalation and Dust Ingestion Exposure to DCHP from	
78	Articles Modeled in CEM 3.2	21
79	Table 2-6. Chemical Migration Rates Observed for DBP	23
80	Table 2-7. Mouthing Durations for Children for Toys and Other Objects	23
81	Table 2-8. Summary of Key Parameters for Products Modeled in CEM 3.2	26
82	Table 2-9. Key Parameters Used in Dermal Models	30
83	Table 2-10. Short-Term Event per Month and Day Inputs	31
84	Table 4-1. Detection and Quantification of DCHP in House Dust from Three Studies	41
85	Table 4-2. Estimates of DCHP Dust Ingestion Per Day from Monitoring, Ages 0–21 Years	42
86	Table 4-3. Estimates of DCHP Dust Ingestion Per Day from Monitoring, Ages 21-80+ Years	42
87	Table 5-1. Weight of Scientific Evidence Summary Per Consumer COU	46
88	Table 5-2. Weight of Scientific Evidence Conclusions for Indoor Dust Ingestion Exposure	47
89	Table 5-3. Summary of Variables from Özkaynak et al. 2022 Dust/Soil Intake Model	49
90	Table 5-4. Comparison between Özkaynak et al. 2022 and Exposure Factors Handbook Dust	
91	Ingestion Rates	51
92		

93 LIST OF FIGURES

94	Figure 2-1. Consumer Pathways and Routes Evaluated in this Assessment
95	Figure 2-2. DCHP Average Absorptive Flux vs. Absorption Time
96	Figure 3-1. Acute Dose Rate for DCHP from Ingestion, Inhalation, and Dermal Exposure Routes in
97	Infants Aged <1 Year, Toddlers Aged 1–2 Years, and Preschoolers Aged 2–5 Years 34
98	Figure 3-2. Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for
99	Middle Childhood Ages 6–10 Years
100	Figure 3-3 Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for
101	Young Teens Aged 11–15 Years and Teenagers and Young Adults Aged 16–20 Years 35
102	Figure 3-4. Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes in
103	Adults Older than 21 Years
104	Figure 3-5. Intermediate Dose Rate for DCHP from Inhalation Exposure Route in Infants Aged <1
105	Year to Middle Childhood Aged 6–10 Years
106	Figure 3-6. Intermediate Dose Rate for DCHP from Inhalation Exposure Route Young Teens Aged
107	11–15 Years to Adults Older than 21 Years
108	Figure 3-7. Chronic Dose Rate for DCHP from Ingestion, Inhalation, Dermal Exposure Routes in
109	Infants Aged <1 Year, Toddlers Aged 1–2 Years, and Preschoolers Aged 3–5 Years 38
110	Figure 3-8. Chronic Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for
111	Middle Childhood Ages 6–10 Years
112	Figure 3-9. Chronic Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for
113	Young Teens Aged 11–15 Years and Teenagers and Young Adults Aged 16–20 Years 38

114	Figure 3-10. Chronic Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes in
115	Adults Older than 21 Years
116	

117 ABBREVIATIONS AND ACRONYMS

- 118ACCAmerican Chemical Council
- 119ADRAverage (or acute) dose rate
- 120CADDChronic Average Daily Dose
- 121 CASRN Chemical Abstracts Service Registry Number
- 122 CDC Center for Disease Control and Prevention
- 123CDRChemical Data Reporting
- 124 CEM Consumer Exposure Model
- 125 CPSC Consumer Product Safety Commission
- 126 CPSIA Consumer Product Safety Improvement Act
- 127 COU Condition of use
- 128 DBP Dibutyl phthalate
- 129 DCHP Dicyclohexyl phthalate
- 130 DIY Do-it-yourself
- 131FDAFood and Drug Administration
- 132 HPCDS High Priority Chemicals Data System
- 133 MCCEM Multi-Chamber Concentration and Exposure Model
- 134 NHANES National Health and Nutrition Examination Survey
- 135OPPTOffice of Pollution Prevention and Toxics
- 136PODPoint of departure
- 137PVAcPolyvinyl acetate120PV/GPolyvinyl acetate
- 138PVCPolyvinyl chloride139SDSSafety data sheet
- 140SVOCSemi volatile organic compound
- 141 TSCA Toxic Substances Control Act
- 1411SCA1 oxic Substances Control Act

142 SUMMARY

143 This technical document is in support of the Toxic Substances Control Act (TSCA) Draft Risk 144 Evaluation for Dicyclohexyl Phthalate (DCHP) (U.S. EPA, 2024f). It provides detailed descriptions of 145 DCHP consumer and indoor exposure assessment. DCHP is a white, crystalline solid with a mild 146 aromatic odor used as a plasticizer in the production of plastics, adhesives, rubber, and resins; see Draft 147 Physical Chemistry and Fate and Transport Assessment for Dicyclohexyl Phthalate (DCHP) (U.S. EPA, 148 2024e). DCHP, either alone or in combination with other phthalates, is also commonly used in the 149 production of plastics and other polymers, in sealants and adhesives for paper food packaging, and as a 150 preservation agent in peroxides. 151 152 This draft assessment considers human exposure to DCHP in consumer products resulting from TSCA 153 conditions of use (COUs). The major routes of exposure considered were ingestion via mouthing, 154 ingestion of suspended dust, ingestion of settled dust, inhalation, and dermal exposure. For inhalation 155 and ingestion exposures, EPA used the Consumer Exposure Model (CEM) to estimate acute and chronic 156 exposures to consumer users and bystanders. Intermediate exposures were calculated from the CEM 157 daily exposure outputs for applicable scenarios in a spreadsheet Draft Consumer Risk Calculator 158 (DCHP) (U.S. EPA, 2024c) outside of CEM because the exposure duration for intermediate scenarios is outside the 60-day modeling period CEM uses. Acute exposures are for an exposure duration of 1 day, 159 160 chronic exposures are for an exposure duration of 1 year, and intermediate are for an exposure duration of 30 days. Confidence in the CEM inhalation and ingestion modeling estimates were robust or 161 moderate depending on product or article scenario. For each scenario, high, medium, and low exposure 162 163 scenarios were developed in which values for duration of use, frequency of use, and surface area were determined based on reasonably available information and professional judgment. Dermal exposures for 164 165 both liquid products and solid articles were calculated in a spreadsheet outside of CEM; see Draft 166 Consumer Exposure Analysis for Dicyclohexyl Phthalate (DCHP) (U.S. EPA, 2024b). CEM dermal modeling uses a dermal model approach that assumes infinite DCHP migration from product to skin 167 168 without considering saturation, which would result in an overestimation of dose and subsequent risk (see 169 Section 2.3 for a detailed explanation). Low, medium, and high exposure scenarios were developed for 170 each product and article scenario by varying values for duration and frequency of dermal contact and 171 area of exposed skin. Confidence in the dermal exposure estimates were moderate depending on 172 uncertainties associated with input parameters. 173

174 The highest DCHP exposure estimated for all scenarios was for ingestion via mouthing of indoor dust 175 collected on children's toys for infants, toddlers, and preschoolers (up to 5 years old). Because mouthing 176 tendencies decrease or cease entirely for children 6 to 10 years old, exposure from mouthing is expected to be larger for infants to 5-year-old children. Because products/articles that do not have a mouthing 177 178 estimate are not expected to have direct mouthing exposures, the ingestion exposure estimates fall below 179 all other exposure routes. Dermal exposures were overall highest followed by inhalation and ingestion 180 across scenarios, COUs, and lifestages. The range of inhalation and ingestion doses for each scenario 181 and lifestage covered several orders of magnitude due to (1) the wide range of DCHP content (weight 182 fractions) for adhesives; (2) wide range of article exposure durations; and (3) various surface area 183 options for similar articles for the low, medium, and high scenario for children's toys. The dermal dose 184 range was smaller for all scenarios driven mainly by exposure durations and frequencies.

185 **1 INTRODUCTION**

DCHP is assigned one CASRN, 84-61-7 under various names: 1,2-benzenedicarboxylic acid,
dicyclohexyl ester; phthalic acid, dicyclohexyl ester; and diclohexyl 1,2-benzenedicarboxylate. DCHP is
a granular solid primarily used as a plasticizer in polyvinyl chloride (PVC) in consumer, commercial,
and industrial applications—although it is also used in adhesives, sealants, paints, coatings, rubbers, and
non-PVC plastics as well as for other applications.

191

192 The consumer and indoor dust exposure assessment requires the identification of products and articles 193 within each TSC condition of use (COU). These included PVC used in solid articles such as electronics 194 containing dye adhesives, foil lacquers, paperboard, and cellophane for packaging, polyvinyl alcohol 195 (PVA), hardener catalysts for concrete and masonry; liquid products including adhesives, sealants, and 196 automotive and construction adhesives. EPA further assembled reasonably available information from 197 2016 and 2020 data reported in the Chemical Data Reporting (CDR) database and consulted a variety of 198 other sources (including published literature, company websites, and government and commercial trade 199 databases and publications) to identify additional COUs for inclusion in the draft risk evaluation (see 200 Table 1-1 for consumer-specific COUs). Consumer products and articles were identified and matched to 201 COUs. Weight fractions of DCHP in specific items were then gathered from a variety of sources, such 202 as safety data sheets (SDSs), databases, and literature reviewed publications. These data were used in 203 this assessment in a screening approach as described in Section 2.1. Although children's toys were not 204 identified as a COU of DCHP, EPA considered data identified in the High Priority Chemicals Data 205 System (HPCDS) (WSDE, 2020) database. The Agency used the identified data to develop children's 206 toys exposure scenarios. This document provides a summary of the exposure doses calculated.

207

208 The migration of DCHP from consumer products and articles has been identified as a potential

209 mechanism of exposure. However, the relative contribution of various consumer goods to overall 210 exposure to DCHP has not been well characterized. The identified uses can result in exposures to

consumers and bystanders (non-product users that are incidentally exposed to the product). For all the

212 DCHP containing consumer products identified, the approach involves addressing the inherent

uncertainties by modeling low, medium, and high exposure scenarios. Due to the lack of comprehensive

data on various parameters and the expected variability in exposure pathways, these scenarios allow for

a robust exploration of the estimated risks associated with DCHP across COUs and various age groups.

216

Because PVC and plastic products are ubiquitous in modern indoor environments, and since DCHP is not chemically bound to many consumer products and articles in which it is incorporated, it can leach, migrate, or evaporate (to a lesser extent based on physical and chemical properties) into indoor air and concentrate in household dust. Exposure to compounds through dust ingestion, dust inhalation, and

dermal absorption is a particular concern for young children between the ages of 6 months and 2 years

as they crawl on the ground and pull-up on ledges, which increases hand-to-dust contact. Children in this

age group also frequently place their hands and objects in their mouths. Therefore, estimated exposures

were assessed and compared for children below and above 2 years old.

225 Table 1-1. Consumer Conditions of Use Table

Life Cycle Stage ^a	Category ^b	Subcategory of Use ^{c,e}	References
	Adhesives and sealants	Adhesives and sealants	(DeWALT, 2024; Lord Corporation, 2024; Midwest Technology Products, 2024; MKT, 2024; Permatex, 2024, 2021; DeWALT, 2020; MKT, 2018; LORD Corporation, 2017)
Consumer Uses	Other articles with routine direct contact during normal use including rubber articles; plastic articles (hard)	Other articles with routine direct contact during normal use including rubber articles; plastic articles (hard)	(<u>U.S. EPA, 2020a; AIA, 2019; MEMA, 2019; MEMA, 2019; U.S. EPA, 2019a</u>)
	Other	Other consumer articles that contain dicyclohexyl phthalate from: inks, toner, and colorants; paints and coatings; adhesives and sealants (<i>e.g.</i> , paper products, textiles, products using cellulose film, etc.)	(HYDRO-GARD, 2024; Hallstar, 2022; LANXESS, 2021; U.S. EPA, 2020b; Earthjustice, 2019; MEMA, 2019; U.S. EPA, 2019b; Gans Ink and Supply, 2018; HYDRO-GARD, 2017a, b; CPSC, 2015)
Disposal	Disposal	Disposal	

227 2 CONSUMER EXPOSURE APPROACH AND METHODOLOGY

- 228 The main steps in performing a consumer exposure assessment are summarized below:
- Identification and mapping of product and article examples following the consumer COU table
 (Table 1-1), product, and article identification.
- 2. Compilation of products and articles manufacturing use instructions to determine patterns of use.
- 3. Selection of exposure routes and exposed populations according to product/article use
 descriptions.
- 4. Identification of data gaps and further search to fill gaps with studies, chemical surrogates or
 product and article proxies, or professional judgement.
- 5. Selection of appropriate modeling tools based on available information and chemical properties.
- 237 6. Gathering of input parameters per exposure scenario.
- 238 7. Parameterization of selected modeling tools.

Consumer products and articles containing DCHP were matched with TSCA COUs appropriate for the anticipated use of the item. Table 2-1 summarizes the consumer exposure scenarios by COU for each product example(s), the relevant exposure routes, an indication of scenarios also used in the indoor dust assessment, and whether the analysis was done qualitatively or quantitatively. The indoor dust assessment uses consumer product information for selected articles with the goal of recreating the indoor environment. The consumer articles included in the indoor dust assessment were selected for their potential to have large surface area for dust collection.

246

247 A quantitative analysis was conducted when the exposure route was deemed relevant based on product 248 or article use description and there was sufficient data to parameterize the model. A qualitative analysis was conducted when data were not available for modeling. The qualitative analysis allowed for a 249 250 discussion of exposure potential based on physical and chemical properties, or available monitoring data 251 should monitoring data be available, even in the absence of quantitative modeling estimates. When a 252 quantitative analysis was conducted, exposure from the consumer COUs was estimated by modeling. 253 Each product or article was individually assessed to determine whether all or some exposure routes were 254 applicable, and approaches were developed accordingly.

255

256 Exposure via inhalation and ingestion routes were modeled using EPA's CEM Version 3.2 (U.S. EPA, 257 2023). Dermal exposure to DCHP-containing consumer products was estimated using a computational framework implemented within a spreadsheet. Refer to Dermal Modeling Approach in Section 2.3 for a 258 259 detailed description of dermal approaches, rationale for analyses conducted outside CEM, and consumer 260 specific dermal parameters and assumptions for exposure estimates. For each exposure route, EPA used the 10th percentile, average, and 95th percentile value of an input parameter (e.g., weight fraction, 261 262 surface area, etc.) to characterize low, medium, and high exposure, where possible and according to 263 condition of use. If only a range was reported, EPA used the minimum and maximum of the range as the 264 low and high values, with the average of the minimum and maximum used for the medium scenario. See 265 Section 2.1 for details about the identified weight fraction data and statistics used in the low, medium, 266 and high exposure scenarios. All CEM and dermal spreadsheet calculations' inputs, sources of 267 information, assumptions, and exposure scenario descriptions are available in the Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP) - Supplemental Information File: Consumer Exposure Analysis 268 269 (U.S. EPA, 2024b). 270

Based on reasonably available information from the systematic review on consumer conditions of use
and indoor dust studies, inhalation of DCHP is possible through DCHP emitted from products and
articles and DCHP sorbed to indoor dust and particulate matter. A detailed discussion of indoor dust

references, sources, and concentrations is available in Sections 4. Due to DCHP's low volatility,

275 negligible or very small gas-phase inhalation exposures are expected. However, DCHP's physical and 276 chemical properties, such as low vapor pressure, low solubility, and high K_{OA} suggest a high affinity for 277 organic matter, which is typically present in household dust. The likelihood of sorption to suspended and 278 settled dust is supported by indoor monitoring data. Section 4.1 reports concentrations of DCHP in 279 settled dust from indoor environments. Due to the presence of DCHP in indoor dust, inhalation and 280 ingestion of suspended dust as well as ingestion of settled dust are both considered as exposure routes in 281 this consumer assessment.

282

Oral exposure to DCHP is also possible through incidental ingestion during product use, transfer of chemical from hand-to-mouth, or mouthing of articles. Dermal exposure may occur via direct contact with liquid products and solid articles during use. Based on these potential sources and pathways of exposures that may result from the conditions of use identified for DCHP, oral and dermal exposures to consumers were assessed.

288

289 Qualitative analysis describing low exposure potential were discussed in Section 2.1, mainly based on 290 physical and chemical properties or product and article use descriptions. For example, given the low 291 volatility of DCHP, emissions to air from solid articles are expected to be relatively low. As such, articles with a small surface area ($< -1 \text{ m}^2$) and articles used outdoors were not assessed for inhalation 292 293 exposure. For items with small surface area for emissions and dust collection, the potential for emission 294 to air and dust is further reduced. To verify this assumption, a CEM test run for a generic 1 m^2 item with 295 30 percent DINP content by weight was carried out. The combined doses from inhalation and dust 296 ingestion ranged four orders of magnitude less than the point of departure (POD) used to assess human 297 health risk in this assessment and are likely to be negligeable as compared to potential exposure by 298 dermal and mouthing routes, which were assessed as appropriate, see Draft Risk Evaluation for 299 Dicyclohexyl Phthalate (DCHP) (U.S. EPA, 2024f). Similarly, solid articles not expected to be mouthed (e.g., building materials, outdoor furniture, etc.) were not assessed for mouthing exposure. Furthermore, 300 301 as DCHP is a low volatility solid that is used primarily as a plasticizer in manufacturing, potential take-302 home exposures are likely too small in comparison to the scenarios considered in this assessment, hence 303 take-home exposures were not further explored.

304

305 EPA assessed acute, chronic, and intermediate exposures to DCHP from consumer COUs. For the acute 306 dose rate calculations, an averaging time of one day is used to represent the maximum time-integrated 307 dose over a 24-hour period in which the exposure event occurs. The chronic dose rate is calculated 308 iteratively at a 30-second interval during the first 24 hours and every hour after that for 60 days, and 309 averaged over one year. Professional judgment and product use descriptions were used to estimate 310 number of events per day and per month for each product, for use in the calculation of the intermediate 311 dose. Whenever professional judgment was used, EPA provided a rationale and description of selected 312 parameters.

313 **2.1 Products and Articles with DCHP Content**

314 Products are generally consumable liquids, aerosols, or semi-solids that are used a given number of 315 times before they are exhausted. Articles are generally solids, polymers, foams, metals, or woods, which 316 are present within indoor environments for the duration of their useful life, which may be several years. 317 The preferred data sources for DCHP content in U.S. consumer goods were safety data sheets (SDS) for 318 specific products or articles with reported DCHP content, peer review literature providing measurements 319 of DCHP in consumer goods purchased in the U.S., and government reports originating in the U.S. with 320 manufacturer reported concentrations. In instances where these data from preferred sources were not 321 available, DCHP content in specific products and articles provided in non-U.S. sources and the EPA 322 Chemical Data Reporting (CDR) rule were reviewed. Manufacturing practices and regulations for

- 323 DCHP in consumer goods are comparable between high income countries and the U.S., so it is
- reasonable to assume that similarly formulated products may be available across these regions. When no data could be found for a specific type of product or article identified as likely to contain DCHP, weight
- fractions from similar products for general classes of items were used (*e.g.*, non-specific adhesives,
- 327 furniture, or textiles). DCHP weight fractions reported in the CDR database were used only when no
- 328 other data could be found for a reported product category. The weight fraction data reported in the CDR
- 329 database may pertain to a finished good in the product category reported, or it could represent a 330 chemical additive that is added to other components during the manufacturing process of the finished
- 331 good. There are considerable uncertainties in weight fraction when using CDR data. The concentration
- value reported in CDR may be regarded as an upper boundary for the DCHP content in finished
- 333 consumer goods.
- 334

EPA further evaluated the products and articles identified to ensure that data was representative of items which may expose U.S. consumers to DCHP. Where possible, SDSs were cross-checked with company websites to ensure that each product could reasonably be purchased by consumers. In instances where a product or article could not be purchased by a consumer, EPA did not evaluate the item in a DIY or application scenario but did determine whether consumers might reasonably be exposed to the specific item as part of a purchased good, including homes and automobiles.

341

342 In addition to DCHP weight fractions, EPA obtained additional information about physical

characteristics and potential uses of specific products and articles from technical specifications,
 manufacturer websites, and vendor websites. These data were used in the assessment needed to define
 exposure scenarios. The following sections provides a summary of specific products and articles with
 DCHP content identified for each item, and Table 2-1 provides a summary of TSCA COUs determined
 for each item and exposure pathways modeled.

348 2.1.1 Solid Articles

349 DCHP has been described to be used in a variety of solid articles. However, weight fraction data for solid articles containing DCHP and currently sold in the U.S. were limited. Consumer product data were 350 351 obtained from SDSs and the High Priority Chemicals Data System (HPCDS) (WSDE, 2020), a database 352 compiling manufacturer reporting requirements per Washington and Oregon safe children's product 353 regulations. The DCHP weight fraction data used in this assessment from the HPCDS database corresponds to the 2017 to 2024 reporting period. Concentration ranges (e.g., 100-500 ppm) based on 354 355 test results or manufacturer knowledge are provided. Additionally, specific products or articles are not 356 identified; only generic categories (e.g., toys/games) are provided.

357 Given the high molecular weight (330.43 g/mol) and low vapor pressure (8.69×10^{-7} mmHg) of DCHP, 358 359 partitioning into air and overlying dust from solid articles is expected to be limited. Consequently, 360 inhalation and dust ingestion exposure for items with small surface area of emissions ($<1 \text{ m}^2$) or those 361 used outdoors are expected to be insignificant as compared to exposure by mouthing and dermal contact. 362 As such, inhalation and dust ingestion were not assessed for these items, see articles with potential for 363 semi-routine dermal exposure. For solid articles where only mouthing and/or dermal contact were assessed, DCHP content is provided for context and was not used directly in exposure calculations for 364 365 these routes (see Section 2.3 for details). For articles assessed for mouthing and/or dermal contact the weight fraction data is used to confirm the presence of DCHP in the article but these data are not used in 366 the dermal and mouthing modeling, see Sections 2.2.3.1 (mouthing) and 2.3 (dermal). Furthermore, 367 368 dermal, and mouthing exposures assessments include high, medium, and low intensity use scenarios for 369 each article using a range of modeling input parameters described in the corresponding sections, such as 370 dermal absorption related parameters and chemical migration rates (mouthing).

371 Children's Toys

- 372 Although children's toys were not identified as a COU of DCHP, EPA considered data identified in the 373 High Priority Chemicals Data System (HPCDS) (WSDE, 2020) database. The Agency used the 374 identified data to develop children's toys exposure scenarios. This document provides a summary of the 375 exposure doses calculated. Children's toys were assessed for DCHP exposure by the inhalation, dust 376 ingestion, dermal, and mouthing routes of exposure. Under the Consumer Product Safety Improvement Act (CPSIA) final rule that went into effect on April 25, 2018, Congress permanently prohibited the sale 377 378 of children's toys or childcare articles containing concentrations of more than 0.1 percent DCHP. While it is possible that some individuals may have children's toys in the home that were produced before the 379 regulation was enacted and/or toys may be sold with non-compliant DCHP content, such scenarios were 380 381 not modeled because relevant data were unavailable. The HPCDS database contained data for DCHP 382 measurements in 20 toy/game items. While there is some uncertainty about the materials these items are 383 manufactured from, based on the limited descriptions in the database, EPA determined that these items 384 are likely composed primarily of plastic and rubber components. DCHP content was reported to be less 385 than 100 ppm (<0.01%) in all toy items. (WSDE, 2020). As such, all scenarios for children's toys were 386 modeled with a weight fraction of 0.0001 w/w (weight per weight).
- 387

388 Electronics containing Dye Adhesive

389 DCHP was identified at 0.1 to 1 percent in dye attach adhesive used in wirebond packaging for 390 semiconductor devices or in automotive cameras (<u>Henkel Corporation, 2019</u>). As the adhesive is used in 391 small quantities and contained within the electronic articles, no exposures are expected during potential 392 use of these items.

393

394 Other articles with potential for semi-routine dermal exposure

395 In the 2020 CDR database, a manufacturer reported that DCHP or a DCHP containing additive was 396 produced for use in small rubber or plastic items with routine contact. Specific items manufactured and 397 weight fraction of DCHP in finished goods were not reported. To determine the kinds of articles which 398 might contain DCHP, U.S. plasticizer manufacturer websites were surveyed for descriptions of use. 399 Only one manufacturer could be identified which clearly markets a plasticizer containing DCHP at 400 present (Parchem, 2024). Potential uses for the DCHP containing plasticizer listed on the product page 401 include heat-seal applications, food wrappers, labels, and packaging adhesives; pharmaceutical labels; 402 foil lacquers; cellophane lacquers; nitrocellulose; ethylcellulose; chlorinated rubber; PVAc; PVC; and 403 printing inks. Consumers may come into contact with materials containing DCHP through handling 404 various packaging, labels, and films. For example, films may be used as wrapping for gift baskets, florist 405 supplies, and product windows on boxes. As films are typically used in smaller items, the primary 406 exposure route is through dermal contact when handling the packaged goods. Although DCHP content 407 was not reported or measured in specific products, this scenario was included for dermal exposure calculations, which does not use weight fractions. Dermal contact events are likely short and/or 408 409 infrequent, but an individual could have appreciable daily contact with multiple items. The items are not 410 expected to be mouthed and the likelihood of inhalation exposure is minimal due to their small surface 411 area and limited time spent in an indoor environment before disposal. Some of the listed uses, such as 412 food packaging materials, may not be chemical substances under TSCA. However, information gathered 413 from these uses was used as a proxy for packaging, wrappers, and labels related to COUs in this

- 414 evaluation.
- 415

416 Outdoor Coated Surfaces/Seating

417 DCHP content was identified in two hardener catalysts which are used with their associated

- 418 waterproofing coating resin products in applications such as concrete, masonry, plaza decks, roof decks,
- 419 balconies, terraces, and stadium seating. The reported DCHP content in the two products was 50 percent
- 420 (CETCO, 2018) and 40 to 55 percent (<u>Hydro-Gard LLC, 2017</u>). However, both products are added to
- resin in small quantities, resulting in significantly lower weight fractions on the finished surface. Based
- on technical documentation provided by manufacturers, the weight fraction of DCHP in applied surface
 coatings is expected to be between 0.001 to 0.024 w/w, depending upon the resin used and mixing ratios
- selected. Dermal exposures were modeled for a scenario where consumers sit on coated surfaces (*e.g.*,
- 424 selected. Definit exposures were induced for a scenario where consumers sit on coated surfaces (e.g., 425 on seats at a sporting event or directly on a terrace). Based on DCHP's waterproofing and weather
- resistant properties and the examples being mainly outdoors EPA anticipated use is outdoors only and
- 427 air exchange rates are large, thus inhalation exposure is expected to be negligible.

428 2.1.2 Liquid and Paste Products

Liquid and paste products with DCHP content were identified by manufacturer SDS. Products with
similar DCHP content and expected use patterns were grouped together for modeling as described
below. Note that for liquid and paste products where only dermal exposure was assessed, DCHP content
is provided here for context and not used directly in exposure calculations for these routes (see Sections
2.2.3 and 2.3 for details).

434

435 Adhesives and Sealants for Small Repairs

436 Two adhesive products were identified with DCHP content. The first product is a multi-purpose 437 household glue for small repairs, with DCHP content of 1 to 5 percent (ITW Permatex, 2018). The 438 second product is an adhesive activator used in small repairs, with DCHP content ranging from 10 to 20 439 percent (WEICON GmbH & Co. KG, 2018). Both products are used in small amounts and have very 440 short working times (<5 min), which limits the potential for inhalation exposure. However, if dermal 441 exposure occurs during use it is possible that the product may not be washed off immediately, 442 potentially resulting in significant exposure. As such, both products were modeled for dermal exposure 443 only. 444

445 Automotive or Construction Adhesives

446 Two bonding adhesives for vehicle maintenance/repair or construction applications were identified. The 447 reported DCHP contents were 1 to 5 percent (LORD Corporation, 2017) and 3 to 5 percent (Ford Motor 448 Company, 2015). The identified products may be used for large repairs to vehicle bodies and were 449 therefore assessed for both inhalation and dermal exposure. DCHP weight fractions used in low, 450 medium, and high exposure scenarios were 0.01, 0.035, and 0.05 w/w.

- 451
- Table 2-1 provides a summary of TSCA COUs determined for each item and exposure pathways
- 453 modeled.

454 Table 2-1. Summary of Consumer COUs, Exposure Scenarios, and Exposure Routes

				Evaluated Routes						
				ıst		Ingestion				
Consumer Condition of Use Category	Consumer Condition of Use Subcategory	Product/Article	Exposure Scenario and Route	Suspended Dust and Vapor Inhalation	Dermal	Suspended Dust	Settled Dust	Mouthing	Qualitative / Quantitative d	
Adhesives and sealants	Adhesives and sealants	Auto or construction bonding adhesive	Use of product in DIY ^{<i>a</i>} large-scale home repair activities. Direct contact during use; inhalation of emissions during use.	~	~	×	×	×	Quantitative	
Adhesives and sealants Adhesives and sealants		Adhesives for small repairs	Use of product in DIY ^{<i>a</i>} small-scale home repair activities. Direct contact during use.	X	~	×	×	×	Quantitative	
Plasticizer in other articles with routine direct contact during normal use including rubber articles; plastic articles (hard)	articles with routine direct contact during normal use includingarticles with routine direct contact during normal use includingpotential for semi-routine contact: labels, nitrocellulose; ethylcellulose; chlorinated		Direct contact during use	X b	~	×	×	×	Quantitative	
Not identified as a COU of DCHP ^e Of DCHP ^e		Children's toys	Collection of toys. Direct contact during use; inhalation of emissions / ingestion of airborne particulate; ingestion by mouthing.	~	~	~	~	~	Quantitative	
Other	Other consumer articles that contain dicyclohexyl phthalate from: inks, toner and colorants; paints and coatings; adhesives and sealants (<i>e.g.</i> , paper	Outdoor coated surfaces/seating	Direct contact during use	x c	~	×	×	×	Quantitative	

				Evaluated Routes					
				ıst		Ingestion			
Consumer Condition of Use Category	Consumer Condition of Use Subcategory Product/Article		Exposure Scenario and Route	Suspended Dust and Vapor Inhalation	Dermal	Suspended Dust	Settled Dust	Mouthing	Qualitative / Quantitative d
	products, textiles, products using cellulose film, etc.)								
Other	Other consumer articles that contain dicyclohexyl phthalate from: inks, toner and colorants; paints and coatings; adhesives and sealants (<i>e.g.</i> , paper products, textiles, products using cellulose film, etc.)	Small articles with the potential for semi-routine contact: labels, and packaging adhesives, foil and cellophane lacquers, and printing inks	Direct contact during use	X b	\checkmark	×	×	×	Quantitative
Other	Other consumer articles that contain dicyclohexyl phthalate from: inks, toner and colorants; paints and coatings; adhesives and sealants (<i>e.g.</i> , paper products, textiles, products using cellulose film, etc.)	Electronics containing dye adhesive	No exposures expected	×	×	×	×	*	Qualitative
Disposal	Disposal	Down the drain products and articles	Down the drain and releases to environmental media	×	×	×	x	×	Qualitative
Disposal	Disposal	Residential end-of-life disposal, product demolition for disposal	Product and article end- of-life disposal and product demolition for	×	×	×	×	×	Qualitative

				Evaluated Routes						
					Dust or on		I	ngestion		
	Consumer Condition of Use Category	Consumer Condition of Use Subcategory	Product/Article	Exposure Scenario and Route	Suspended Di and Vapor Inhalation	Dermal	Suspended Dust	Settled Dust	Mouthing	Qualitative / Quantitative d
				disposal						

DIY^a – Do-it-Yourself

Scenario is considered either qualitatively or quantitatively in this assessment.

Scenario was deemed unlikely based on low volatility and small surface area, likely negligible gas and particle phase concentration for inhalation, low possibility of mouthing based on product use patterns and targeted population age groups, and/or low possibility of dust on surface due to barriers or low surface area for dust ingestion.

Scenario was deemed unlikely based on low volatility and small surface area and likely negligible gas and suspended particle phase concentration.

 \mathbf{x}^{c} Outdoor use with significantly higher ventilation minimizes inhalation.

^d Quantitative applies to green check marks and qualitative applies to red "x" marks for the routes that were deemed unlikely (Sections 2.1.1 and 2.1.2 or assessed qualitatively using physical and chemical properties (Disposal).

^e Although children's toys were not identified as a COU of DCHP, EPA considered data identified in the High Priority Chemicals Data System (HPCDS) (<u>WSDE</u>, <u>2020</u>) database and used it to provide an exposure assessment.

456 *Qualitative Assessments*

- 457 EPA performed qualitative assessments of the COU summarized in Table 2-2. A qualitative discussion
- 458 using physical and chemical properties and monitoring data for environmental media was performed to
- 459 support conclusions about down-the-drain and disposal practices and releases to the environment.
- 460

461 **Table 2-2. COUs and Products or Articles Without a Quantitative Assessment**

Consumer Use Category	Consumer Use Subcategory	Product/Article	Comment
Disposal	Disposal	Down the drain products and articles	No quantitative assessment done due to limited information on source attribution of the consumer COUs in drain water or wastewater.
Disposal	Disposal	Residential end- of-life disposal, product demolition for disposal	No quantitative assessment done due to limited information on source attribution of the consumer COUs in landfills.
Other	Other consumer articles that contain dicyclohexyl phthalate from: inks, toner and colorants; paints and coatings; adhesives and sealants (<i>e.g.</i> , paper products, textiles, products using cellulose film, etc.)	Electronics containing dye adhesive	No exposures are expected during potential use of these items because the adhesive is used in small quantities and contained within the electronic articles.


462

463 Environmental releases may occur from consumer products and articles containing DCHP via the end-464 of-life disposal and demolition of consumer products and articles in the built environment or landfills, as 465 well as from the associated down-the-drain release of DCHP. It is difficult for EPA to quantify these 466 end-of-life and down-the-drain exposures due to limited information on source attribution of the 467 consumer COUs. In previous assessments, EPA has considered down-the-drain analysis for consumer 468 products scenarios where there is reasonably foreseen exposure scenarios where it can be assumed the consumer products (e.g., sealants) may be discarded directly down-the-drain. For example, adhesives 469 and sealants can be disposed down-the-drain when users wash their hands, brushes, sponges, and other 470 471 product applying tools. Although EPA acknowledges that there may be DCHP releases to the 472 environment via the cleaning and disposal of adhesives and sealants, the Agency did not quantitatively 473 assess these scenarios due to limited information, monitoring data, or modeling tools. In addition, 474 DCHP- containing products can be disposed and taken to landfills when users no longer have use for 475 them or the products have reached the product shelf life. All other solid products and articles in Table 476 2-1 can be disposed in landfills, or other waste handling locations that properly manage the disposal of 477 products like adhesives and sealants and other solid articles. DCHP is expected to be persistent as it 478 leaches from consumer products disposed of in landfills. Due to slight water solubility, DCHP is likely 479 to be present in landfill leachate up to its aqueous limit of solubility (1.48 mg/L). However, due to its 480 affinity for organic carbon, DCHP is expected to be immobile in groundwater. And even in cases where 481 landfill leachate containing DCHP were to migrate to groundwater, DCHP would likely partition from 482 groundwater to organic carbon present in the subsurface (U.S. EPA, 2024d).

483 **2.2 Inhalation and Ingestion Modeling Approach**

The CEM Version 3.2 (<u>U.S. EPA, 2023</u>) was selected for the consumer exposure modeling as the most appropriate model based on the type of input data available for DCHP-containing consumer products. The advantages of using CEM to assess exposures to consumers and bystanders are as follows:

- CEM model has been peer-reviewed (<u>ERG, 2016</u>);
- CEM accommodates the distinct inputs available for the products and articles containing DCHP,
 such as weight fractions, product density, room of use, frequency, and duration of use, see
 Section 2.2.3 for specific product and article scenario inputs; and
- CEM uses the same calculation engine to compute indoor air concentrations from a source as the higher-tier Multi-Chamber Concentration and Exposure Model (MCCEM) but does not require measured chamber emission values (which are not available for DCHP).
- 494 CEM has capabilities to model exposure to DCHP from both products and articles containing the
- 495 chemical. Products are generally consumable liquids, aerosols, or semi-solids that are used a given
- 496 number of times before they are exhausted. Articles are generally solids, polymers, foams, metals, or
- 497 woods, which are present within indoor environments for the duration of their useful life, which may be
- 498 several years. Figure 2-1 displays the embedded models within CEM 3.2.
- 499



500

- 501 The green squares in the figure refer to dermal exposures, red squares refer to ingestion exposures, and
- 502 purple squares refer to inhalation exposures within CEM.

503 Figure 2-1. Consumer Pathways and Routes Evaluated in this Assessment

504

505 CEM 3.2 generates exposure estimates based on user-provided input parameters and various

506 assumptions (or defaults). The model contains a variety of pre-populated scenarios for specific product

507 and article categories and allows the user to define generic categories for any product or article where

508 the prepopulated scenarios are not adequate. User inputs for physical and chemical properties of

509 products and articles are utilized to calculate emission profiles of SVOCs. There are six emission

- 510 calculation profiles within CEM (E1 to E6) that represent specific use conditions and properties of 511 various products and articles. A description of these models is summarized in the CEM user guide and
- 512 associated appendices <u>https://www.epa.gov/tsca-screening-tools</u>.
- 513
- 514 CEM 3.2 estimates acute dose rates and chronic average daily doses for inhalation, ingestion, and
- 515 dermal exposures of consumer products and articles. However, for the purpose of this assessment, EPA
- 516 perform dermal calculations outside of CEM, see Section 2.3 for approach description and input
- 517 parameters. CEM 3.2 acute exposures are for an exposure duration of 1 day, and chronic exposures are
- 518 for an exposure duration of 1 year. The model provides exposure estimates for various lifestages. EPA
- 519 made some adjustments to match CEM's lifestages to those listed in the Center for Disease Control and 520 Prevention (CDC) guidelines (CDC, 2021) and *EPA's A Framework for Assessing Health Risks of*
- 521 *Exposures to Children* (U.S. EPA, 2006). CEM lifestages are re-labeled from this point forward as 522 follows:
- 523 Adult (≥ 21 years) \rightarrow Adult
- Youth 2 (16–20 years) \rightarrow Teenager and young adult
- 525 Youth 1 $(11-15 \text{ years}) \rightarrow$ Young teen
- 526 Child 2 $(6-10 \text{ years}) \rightarrow \text{Middle childhood}$
- 527 Child 1 $(3-5 \text{ years}) \rightarrow \text{Preschooler}$
 - Infant 2 $(1-2 \text{ years}) \rightarrow \text{Toddler}$
- 529 Infant 1 $(<1 \text{ year}) \rightarrow \text{Infant}$

530 Exposure inputs for these various lifestages are provided in the EPA's CEM Version 3.2 Appendices.

531

528

2.2.1 Inhalation and Ingestion Modeling for Products

532 The calculated emission rates are then used in a deterministic, mass balance calculation of indoor air 533 concentrations. However, CEM employs different models for products and articles. For products, CEM 534 3.2 uses a two-zone representation of the building of use when predicting indoor air concentrations. 535 Zone 1 represents the room where the consumer product is used. Zone 2 represents the remainder of the building. Each zone is considered well-mixed. The model allows for further division of Zone 1 into a 536 537 near field and far field to accommodate situations where a higher concentration of product is expected very near the product user during the period of use. Zone 1-near field represents the breathing zone of 538 539 the user at the location of the product use, while Zone 1-far field represents the remainder of the Zone 1 room. The modeled concentrations in the two zones are a function of the time-varying emission rate in 540 541 Zone 1, the volumes of Zones 1 and 2, the air flows between each zone and outdoor air, and the air flows 542 between the two zones. Following product use, the user and bystander may follow one of three pre-543 defined activity patterns: full time worker, part time worker, and stay-at-home. The activity use pattern 544 determines which Zone is relevant for the user and bystander and the duration of the exposures. The user 545 and bystander inhale airborne concentrations within these zones, which can vary over time, resulting in 546 the overall estimated exposure for each individual. The stay-at-home activity pattern was selected for 547 this assessment for all scenarios as the most conservative behavior pattern for a screening approach, with 548 the option for further refinement should risk be identified in the screening-level analysis. For the "Stay-549 at-Home" activity pattern used in these analyses, both users and bystanders are assumed to be in the 550 home the majority of the day (20 hours).

551

552 CEM default air exchange rates for the building are from the *Exposure Factors Handbook* (U.S. EPA,

553 <u>2011c</u>). The default interzonal air flows are a function of the overall air exchange and volume of the

building as well as the openness of the room, which is characterized in a regression approach for closed

rooms and open rooms (U.S. EPA, 2023), see Section 2.2.3 for product scenario specific selections of

556 environment such as living room vs. whole house, or indoor vs. outdoor and the air exchange rate used 557 per environment selection. Kitchens, living rooms, and the garage area are considered more open, with an interzonal ventilation rate of 109 m³/hour. Bedrooms, bathrooms, laundry rooms, and utility rooms 558 are considered less open, and an interzonal ventilation rate of 107 m³/hour is applied. In instances where 559 the whole house is selected as the room of use, the entire building is considered zone 1, and the 560 interzonal ventilation rate is therefore equal to the negligible value of 1×10^{-30} m³/hour. In instances 561 where a product might be used in several rooms of the house, air exchange rate was considered in the 562 563 room of use to ensure that effects of ventilation were captured.

2.2.2 Inhalation and Ingestion Modeling for Articles

For articles, the model comprises an air compartment (including gas phase, suspended particulates) and 565 a floor compartment (containing settled particulates). SVOCs emitted from articles partition between 566 indoor air, airborne particles, settled dust, and indoor sinks over time. Multiple articles can be 567 568 incorporated into one room over time by increasing the total exposed surface area of articles present within a room. CEM 3.2 models exposure to SVOCs emitted from articles via inhalation of airborne gas-569 and particle-phase SVOCs, ingestion of previously inhaled particles, dust ingestion via hand-to-mouth 570 571 contact, and ingestion exposure via mouthing. Abraded particles are first emitted to the air and thereafter 572 may deposit and resuspend from the surfaces. Abraded particles like suspended and settled particulate, are subject to cleaning and ventilation losses. Abraded particles, both in the suspended and settled 573 574 phases, are not assumed to be in equilibrium with the air phase. Hence, the chemical transfer between 575 particulates and the air phase is kinetically modeled in terms of two-phase mass transfer theory. In 576 addition, abraded particles settled on surfaces are assumed to have a hemispherical area available for 577 emission, whereas those suspended in the air have a spherical area available for emission.

579 In inhalation scenarios where DCHP is released from an article into the gas-phase, the article inhalation 580 scenario tracks chemical transport between the source, air, airborne and settled particles, and indoor 581 sinks by accounting for emissions, mixing within the gas phase, transfer to particulates by partitioning, 582 removal due to ventilation, removal due to cleaning of settled particulates and dust to which DCHP has 583 partitioned, as well as sorption or desorption to/from interior surfaces. The emissions from the article 584 were modeled with a single exponential decay model. This means that the chronic and acute exposure 585 duration scenarios use the same emissions/air concentration data based on the weight fraction of the 586 chemical in the article but have different averaging times. The acute data uses concentrations for a 24-587 hour period at the peak of the simulated emissions, while the chronic data was averaged over the entire 588 1-year period. Because air concentrations for most of the year are significantly lower than the peak 589 value, the air concentration used in chronic dose calculations are usually lower than that used to 590 calculate an acute dose.

591

578

564

2.2.3 CEM Modeling Inputs and Parameterization

The COUs that were evaluated for DCHP consisted of both products and articles. The embedded models within CEM 3.2 that were used for DCHP are listed in Table 2-3 below. As dermal exposure was modeled separately, only inhalation and ingestion routes were evaluated in CEM.

596 Table 2-3. CEM 3.2 Model Codes and Descriptions

Model Code	Description
E1	Emission from Product Applied to a Surface Indoors Incremental Source Model
E2	Emission from Product Applied to a Surface Indoors Double Exponential Model
E3	Emission from Product Sprayed
E6	Emission from article placed in environment
A_INH1	Inhalation from article placed in environment
A_ING1	Ingestion after inhalation
A_ING2	Ingestion of article mouthed
A_ING3	Incidental ingestion of dust
P_ING1	Ingestion of Product Swallowed
P_INH2	Inhalation of Product Used in an Environment

597

598 Table 2-4 presents a crosswalk between the COU subcategories with either a predefined or generic 599 scenario. Models were generated to reflect specific use conditions as well as physical and chemical properties of identified products and articles. In some cases, one COU mapped to multiple scenarios, and 600 601 in other cases one scenario mapped to multiple COUs. Table 2-4 provides data on emissions model and 602 exposure pathways modeled for each exposure scenario. Emissions models were selected based upon 603 physical and chemical properties of the product or article and application use method for products. Exposure pathways were selected to reflect the anticipated use of each product or article. The article 604 605 model Ingestion of article mouthed (A ING2) was only evaluated for the COUs where it was anticipated that mouthing of the product could occur. For example, it is unlikely that a child would mouth flooring 606 or wallpaper, hence the A ING2 Model was deemed inappropriate for estimating exposure for these 607 COUs. Similarly, solid articles with small surface area are not anticipated to contribute significantly to 608 609 inhalation or ingestion of DCHP sorbed to dust/PM and were therefore not modeled for these routes 610 (A ING1, A ING3). For products and articles assessed for dermal exposure only (concrete sealants on 611 outdoor seating surfaces, small articles with semi-routine contact, and adhesives for small repairs), modeling was performed outside of CEM as described in Section 2.3; these items are therefore not 612 included in Table 2-4. 613

614

Table 2-4. Crosswalk of COU Subcategories, CEM 3.2 Scenarios, and Relevant CEM 3.2 Models Used for Consumer Modeling

Consumer COU Category and Subcategory	Product/Article	Emission Model	Exposure Route	Exposure Pathway Model and CEM Saved Analysis
Adhesives and sealants Adhesives and sealants	Automotive Adhesives	E1	Inhalation	Glue and adhesives (small scale); P_INH2 (Near-field/Far-field)
Not identified as a COU of DCHP	Children's Toys	E6	Inhalation, ingestion of suspended and settled dust, and mouthing	Rubber articles: with potential for routine contact (baby bottle nipples, pacifiers, toys); A_INH1, A_ING1, A_ING2, A_ING3

617

In total, the specific products representing three COUs categories and three subcategories for DCHP

619 were mapped to five scenarios. Relevant consumer behavioral pattern data (*i.e.*, use patterns) and

620 product-specific characteristics were applied to each of the scenarios and are summarized in Sections

621 2.2.3.1 and 2.2.3.2.

2.2.3.1 Key Parameters for Articles Modeled in CEM

623 Key input parameters for articles vary based on the exposure pathway modeled. For inhalation and dust ingestion, higher concentrations of DCHP in air and dust result in increased exposure. This may occur 624 due to article specific characteristics that allow for higher emissions of DCHP to air, and/or environment 625 626 specific characteristics such as smaller room volume and lower ventilation rates. Key parameters that 627 control DCHP emission rates from articles in CEM 3.2 models are weight fraction of DCHP in the material, density of article material (g/cm^3) , article surface area (m^2) , and surface layer thickness (cm); 628 an increase in any of these parameters results in increased emissions and greater exposure to DCHP. A 629 630 detailed description of derivations of key parameter values used in CEM 3.2 models for articles is provided below, and a summary of values can be found in Table 2-5. Note that articles not modeled for 631 632 inhalation exposure are not included in the table.

633

622

634 Weight fractions of DCHP were calculated for children's toys as outlined in Section 2.1.1. Material

635 density was assumed to be a standard value for PVC of 1.4 g/cm³. Article surface layer thickness was 636 taken from CEM default values for scenarios with emissions from the same or similar solid material.

637 CEM default values for parameters used to characterize the environment (use volume, air exchange rate,
 638 and interzonal ventilation rate) were used.

639

640 Due to the high variability and uncertainty of article surface areas, high, medium, and low values were 641 estimated with the goal of capturing a reasonable range of values for this parameter. Children's toys 642 generally have a small surface area for an individual item, but consumers may have many of the same 643 type of toy in a home. As such, surface area for children's toys was estimated by assuming that a home has several items containing DCHP rather than one. Estimated values were based on EPA's professional 644 645 judgment of the number and size of toys present in a bedroom. Low intensity use scenario was based on 5 small toys measuring 15 cm by 10 cm by 5 cm, the medium intensity use scenario was based on 20 646 medium toys measuring 20 cm by 15 cm by 8 cm, and high intensity use scenario was based on 30 large 647 toys measuring 30 cm by 25 cm by 15 cm.

648 649

Table 2-5. Summary of Key Parameters for Inhalation and Dust Ingestion Exposure to DCHP from Articles Modeled in CEM 3.2

Article	Exposure Scenario Level	Weight Fraction ^a	Density (g/cm ³) ^b	Article Surface Area (m ²) ^c	Surface Layer Thickness (cm) ^d	Use Environment ^e	Use Environ- ment and Volume (m ³) ^d	Interzone Ventilation Rate (m ³ /h) ^d
~	High	0.001	1.4	9.45				
Children's toys $(new)^{f}$	Med	0.001		2.32	0.01	Bedroom	36	107.01
toys (new)*	Low	0.001		0.28				

^{*a*} See Section 2.1.1 for weight fraction sources and discussion.

^b Used density of PVC from various sources, see *DCHP Draft Consumer Exposure Analysis Spreadsheet* (U.S. EPA, 2024b).

^c See text related to article in this section.

^d CEM default for the emission scenario and saved analysis.

^e Professional judgment based on likeliness of article presence.

^f Toys scenarios consider a potential future application of the U.S. Consumer Product Safety Commission (CSPC) final phthalates rule established in 2017 (16 CFR part 1307) that bans children's toys and childcare articles from containing more than 0.1% of five other phthalates and although DCHP is not currently part of this rule and the identified weight fractions did not exceed 0.1%, this consideration can assist future ruling decisions for DCHP.

653 For mouthing exposure, key parameters include the rate of chemical migration from the article to saliva $(ug/cm^2/hr)$, surface area mouthed (cm^2) , and duration of mouthing (min/day). Derivation of these inputs

- 654 is outlined below. 655
- 656

657 **Chemical Migration Rate**

658 Phthalates added to plastic products are not chemically bound to the polymer matrix, allowing for migration through the material and release into saliva during mouthing. The rate of phthalate migration 659 660 and release to saliva depends upon several factors, including physicochemical properties of the article polymer matrix, phthalate concentration in the polymer, physical mechanics of the individual's mouth 661 during mouthing (e.g., sucking, chewing, biting) and chemical makeup of saliva. In addition, 662 663 physicochemical properties of the specific phthalate such as size, molecular weight, and solubility have 664 a strong impact on migration rate to saliva.

665

666 While there has been considerable investigation of chemical migration rates of phthalates from plastic articles to saliva, rate measurements of DCHP specifically have not been extensively studied. However, 667 668 chemical migration rates for dibutyl phthalate (DBP) are better characterized and may be used as a surrogate. The physical and chemical characteristics that are known to affect chemical migration rates 669 670 are similar between DCHP and DBP, but the larger size, higher molecular weight, and lower solubility 671 of DCHP as compared to DBP can be expected to result in a slower rate of migration through the polymer matrix and less partitioning to saliva for DCHP. Thus, using chemical migration rates of DBP 672 673 to calculate the DCHP dose received during mouthing will provide a health protective estimate.

674

675 Chemical migration rates of phthalates to saliva may be measured by *in vitro* or *in vivo* methods. While 676 measurement assays may be designed to mimic mouthing conditions, there is not a consensus on what 677 constitutes standard mouthing behavior. As a result, there is considerable variability in assay methods, 678 which is also expected to affect the results. Because of the aggregate uncertainties arising from 679 variability in physical and chemical composition of the polymer, assay methods for *in vitro* 680 measurements, and physiological and behavioral variability in *in vivo* measurements, migration rates 681 observed from a single assay condition were not considered adequate for estimating this parameter. The 682 chemical migration rate of DCHP was estimated based on DBP chemical migration data compiled in a 683 review published by the Denmark Environmental Protection Agency in 2016 (DTI, 2016). For this 684 review, data were gathered from existing literature for *in vitro* migration rates from soft PVC to artificial 685 sweat and saliva, as well as in vivo tests when such studies were available. The authors compiled 23 686 values from three studies (Danish EPA, 2010; Niino et al., 2003; Niino et al., 2001) for chemical migration rates of DBP from a variety of consumer goods measured with varying mouthing approaches, 687 688 such as sucking, or chewing, or liking. These values were then subdivided into mild, medium, and harsh 689 categories based on the mouthing approach used to estimate migration, but no data were found for DBP from assays using a medium condition. Reported values are shown in Table 2-6.

690

691

692 While there is considerable variability in the measured migration rates, there was not a clear correlation 693 between weight fraction of DBP in the article and chemical migration rate. Mean values for chemical 694 migration rates of DBP under mild and harsh assay conditions were used in the low and high exposure 695 scenarios, respectively. The midpoint between the two values was used in the medium exposure 696 scenario.

698 **Table 2-6. Chemical Migration Rates Observed for DBP**

	Migration Rate (µg/cm²/hr) ^a							
Mouthing Approach	Min	Mean (Standard Deviation)	Max					
Mild	0.001	$0.17^{b} (0.24)$	0.66					
Harsh	1.17	48.5 ^b (46.9)	144.8					
^a Information from Tables 17, 18, and 19 in (<u>DTI, 2016</u>) ^b Selected values for assessment.								
The DBP migration rates we	re used as a DCHP surrogate	in this assessment. Due t	o lack of DBP					

medium mouthing approaches, EPA used the values reported for mild mouthing approaches.

699

700 Mouthing Surface Area

The parameter "mouthing surface area" refers to the specific area of an object that comes into direct

contact with the mouth during a mouthing event. A standardized value of 10 cm² for mouthing surface

area is commonly used in studies to estimate mouthing exposure in children (Danish EPA, 2010; Niino

704 <u>et al., 2003; Niino et al., 2001</u>). This standard value is based on empirical data reflecting typical

mouthing behavior in young children, providing a reliable basis for estimating exposure levels and

potential health risks associated with mouthing activities. The value of 10 cm^2 was thus chosen for all

707 mouthing exposure models for children.708

709 *Mouthing Duration*

710 Mouthing durations were obtained from the *Exposure Factors Handbook*, Table 4-23 (U.S. EPA, 2011c)

which provides mean mouthing durations for children between 1 month and 5 years of age, broken down

by age groups expected to be behaviorally similar. Values are provided for toys, pacifiers, fingers, and

other objects. For this assessment, only values for toys were used. The data provided in the Handbook

was broken down into more age groups than CEM. For example, it provides different mouthing

durations for infants 12 to 15 months, 15 to 18 months, 18 to 21 months, and 21 to 24 months of age;

716 CEM, in contrast, has only one age group for infants under 1 year of age.

717

To determine the mouthing duration in CEM, all relevant data in the *Exposure Factors Handbook* tables (U.S. EPA, 2011a) were considered together. The minimum value by item type within each age group was used in the low exposure scenario, maximum value was used in the high exposure scenario, and the mean value (average across the age groups provided in the Handbook) was used in the medium exposure scenario as shown in Table 2-7.

723

724Table 2-7. Mouthing Durations for Children for Toys and Other Objects

	Estimated 1	Mean Daily M (min/	louthing Dura /day) ^a	Mouthing Durations for CEM Age Groups (min/day)				
Itom		Reported	Age Group	CEM Age Group: Infants <1 year				
Item Mouthed	1–3 months 3–6 months 6–		6–9 months	9–12 months	High Exposure Scenario ^b	Med Exposure Scenario ^c	Low Exposure Scenario ^d	
Тоу	1.0	28.3	39.2	23.07	39.2	22.9	1.0	
T		Reported	Age Group		CEM Age Group: Infants 1–2 years			
Item Mouthed	12–15 months	15–18 months	18–21 months	21–24 months	High Exposure Scenario	Med Exposure Scenario	Low Exposure Scenario	

	Estimated Mean Daily Mouthing Duration Values (min/day) ^a				Mouthing Durations for CEM Age Groups (min/day)			
Тоу	15.3	16.6	11.1	16.6	14.7	11.1		
Itom		Reported	Age Group	CEM Age Group: Small Child 3–5 years				
Item Mouthed	2 years	3 years	4 years 5 years		High Exposure Scenario	Med Exposure Scenario	Low Exposure Scenario	
Тоу	12.4	11.6	3.2	1.9	12.4	7.3	1.9	

^a Table 4-23 in *Exposure Factors Handbook* (U.S. EPA, 2011a)

^b High exposure scenario value was the largest of the reported mouthing durations for each age group.

^c Med (medium) exposure scenario was calculated as the mean of the high and low exposure scenarios selected values.

^d Low exposure scenario value was the lowest of the reported mouthing durations for each age group.

725

2.2.3.2 Key Parameters for Liquid and Paste Products Modeled in CEM

726 CEM models for liquid and paste products only evaluated exposure by inhalation, while dermal 727 exposures were modeled outside of CEM, see Section 2.3. Higher concentrations of DCHP in air results 728 in increased inhalation exposure. This may occur due to product formulation or use patterns that allow 729 for higher emissions of DCHP to air and/or environment specific characteristics such as smaller room volume and lower ventilation rates. Key parameters that control DCHP emission rates from products in 730 731 CEM 3.2 models are weight fraction of DCHP in the formulation, duration of product use, mass of 732 product used, and frequency of use. Any increase in these parameters results in higher chemical 733 exposure from product use.

734

735 Adhesive for small repairs products, assessed for dermal contact only (see Table 2-1), were not modeled with CEM. In the dermal exposure modeling the weight fraction data are used to confirm the presence of 736 737 DCHP in the product but are not used as a model input (see Section 2.3). Dermal exposure assessments 738 include high, medium, and low intensity use scenarios for each product using a range of modeling input 739 parameters described in Section 2.3, such as dermal absorption, duration, frequency of the contact. 740 Automotive adhesives were assessed for inhalation exposures in addition to dermal exposures using the 741 available weight fraction ranges, and various CEM inputs for the high, medium, and low intensity use 742 scenarios as shown in Table 2-8. CEM does not have default inputs for automotive adhesive products. 743 As such, values for exposure scenario key parameters were based on professional judgement which 744 incorporated information from product labels and information obtained from an informal survey of 745 customer reviews on e-commerce sites. Product densities were taken from product specific technical specifications. A detailed description of derivations of other key parameter values used in CEM 3.2 746 747 models for automotive adhesives is provided below, and a summary of values can be found in Table 2-8. 748 Note that articles not modeled for inhalation exposure are not included in Table 2-8. 749

750 Mass of Product Used

For automotive adhesives, the mass of product used was based on the reasonable assumption that the volume in which products are sold is adequate for the tasks they are intended for. For high exposure scenarios, it was assumed that the entire mass of the larger format product container, 210 ml, is used (Ford Motor Company, 2015). The low exposure scenario assumed that the entire mass of the smaller format product container, 130 ml, was used (Ford Motor Company, 2015). Medium exposure scenario assumed the average of these two values.

757

758 Duration of Use

Automotive adhesives may be used for large projects, but the relatively short working time for these

760 products limits the duration of use. As such, these products were modeled at use durations of 120, 60,

- and 30 minutes for the high, medium, and low intensity use scenarios, respectively.
- 762
- 763 Frequency of Use
- An informal survey of reviews posted by customers on e-commerce sites indicated that both product
- types are used primarily for large repair projects that require significant preparation and clean up. As
- such, it was assumed that individuals may use these products for one project on a yearly basis that may
- take 2 days to complete.
- 768

769 **Table 2-8. Summary of Key Parameters for Products Modeled in CEM 3.2**

Product	Exposure Scenario Level	Weight Fraction ^a	Density (g/cm ³) ^b	Duration of Use (Hr)	Product Mass Used (g)	Freq. of Use (year ⁻¹)	Freq. of Use (day ⁻¹)	Use Environ. Volume (m ³) ^c	Air Exchange Rate, Zone 1 and Zone 2 $(h^{-1})^d$	Interzone Ventilation Rate (m ³ /h) ^d
	High	0.05		120	302.6					
Automotive Adhesives	Med	0.035	1.78	60	151.3	2	1	Garage; 90	0.45	108.98
	Low	0.01		30	75.7					

^{*a*} See Section 2.1.2. High intensity use value is the reported range maximum, the low intensity use value is the reported range minimum, and the medium intensity use value is the mean from the reported maximum and low.

^b Used product SDS reported density value, (LORD Corporation, 2017) and (Ford Motor Company, 2015).

^e Use environment was determined based on product manufacturer use description.

^d CEM default. For all scenarios, the near-field modeling option was selected to account for a small personal breathing zone around the user during product use in which concentrations are higher, rather than employing a single well-mixed room. A near-field volume of 1 m³ was selected.

771 2.3 Dermal Modeling Approach

This section summarizes the available dermal absorption data related to DCHP, the interpretation of the
 dermal absorption data, and dermal absorption modeling efforts. The uncertainties associated with
 dermal absorption estimation are discussed in Section 4.

775

776 DCHP is a plasticizer, additive, and impurity in adhesives in relatively small amounts (see Section 2.1). 777 In addition to polymer additive and plasticizer, DCHP can also be incorporated in the product 778 formulation process as a phlegmatizer. Although inhalation and ingestion pathways were modeled using 779 CEM (see Section 2.2), dermal modeling for liquid and solid products was done using the approach 780 described below. For liquid and solid products, EPA used the steady-state permeability coefficient 781 equations defined within the CEM model in a computational approach that bypassed the need for certain 782 inputs required by CEM such as weight fractions and migration rates. For liquid products, the 783 concentration of DCHP often exceeds its saturation concentration because DCHP molecules form weak 784 chemical bonds with polymer chains in the product/article that favors migration out of the polymer. During direct dermal contact, DCHP can migrate to the aqueous phase available in the skin surface or be 785 786 weakly bound to the polymer. The fraction of DCHP associated with polymer chains is less likely to 787 contribute to dermal exposure as compared to the aqueous fraction of DCHP because the chemical is 788 strongly hydrophobic. As such, use of the CEM model for dermal absorption, which relies on total 789 concentration rather than aqueous saturation concentration, would greatly overestimate exposure to 790 DCHP in liquid chemicals.

791

DCHP dermal specific data were not identified via the systematic review process. EPA used a dermal absorption modeling approach to characterize consumer dermal exposures to liquids or formulations and solids or articles containing DCHP (Section 2.3.2). Dermal exposures to vapors are not expected to be significant due to the extremely low volatility of DCHP, and therefore, are not included in the dermal exposure assessment of DCHP.

797

2.3.1 Flux-Limited Dermal Absorption Approach

When estimating dermal absorption of finite doses (*i.e.*, typically 1 to 10 mg/cm² for solids, (<u>OECD</u>, 2004)), it is important to consider the relationship between the applied dermal load and the rate of dermal absorption. Specifically, the work of Kissel (2011) suggests the dimensionless term N_{derm} to assist with interpretation of dermal absorption data. The term N_{derm} represents the ratio of the experimental load (*i.e.*, application dose) to the steady-state absorptive flux for a given experimental duration as shown in the following Equation 2-1.

804

805 Equation 2-1. Relationship between Applied Dermal Load and Rate of Dermal Absorption

experimental load $\left(\frac{mass}{area}\right)$

$$N_{derm} = \frac{(ureu)}{steady - state flux \left(\frac{mass}{area \cdot time}\right) \times experimental duration (time)}$$

807

806

Kissel (2011) indicates that high values of N_{derm} (>>1) suggest that supply of the material is in surplus, and that the dermal absorption is considered "flux-limited"; whereas, lower values of N_{derm} indicate that absorption is limited by the experimental load and would be considered "delivery-limited." Furthermore, Kissel (2011) indicates that values of percent absorption for flux-limited scenarios are highly dependent on the dermal load and should not be assumed transferable to conditions outside of the experimental conditions. Rather, the absorptive flux should be utilized for estimating dermal absorption of flux-

814 limited scenarios.

Typical consumer scenario dermal loadings range from 1 to 10 mg/cm² and exposure durations range 816 817 from 1 to 24 hours. To estimate N_{derm} for consumer exposure to DCHP, EPA assumed a typical dermal loading estimate of 1 mg/cm² from the range of exposure durations, 24 hours, as it would yield the 818 smallest N_{derm} value under consideration, and an average absorptive flux from 24 hours exposure of 819 2.44×10^{-5} mg/cm²/h (see Section 2.3.2 for details on how this value was selected) as shown below. 820

821 822

$$N_{derm} = \frac{1 \ mg/cm^2}{2.44 \times 10^{-5} \frac{mg}{cm^2 \cdot h} \times 24h} = 1.7 \times 10^3$$

823

824 Because $N_{derm} >> 1$ for a typical consumer dermal exposure scenario, it is shown that the absorption of 825 DCHP is expected to be flux-limited even at finite doses, and that percent absorption should not be

826 considered transferrable across exposure conditions.

2.3.2 Flux-Limited Dermal Absorption for Liquids and Solids

827 828 The first step in modeling dermal absorption through aqueous media is to estimate the steady-state 829 permeability coefficient, K_p (cm/hr). EPA utilized the CEM K_p equation (U.S. EPA, 2023) to estimate the steady-state aqueous permeability coefficient of DCHP as 0.012 cm/hr. Next, EPA relied on 830 831 Equation 3.2 from the Risk Assessment Guidance for Superfund (RAGS), Volume I: Human Health 832 Evaluation Manual, (Part E: Supplemental Guidance for Dermal Risk Assessment) (U.S. EPA, 2004), 833 which characterizes dermal uptake (through and into skin) for aqueous organic compounds. Specifically, 834 Equation 3.2 from U.S. EPA (2004), also shown in Equation 2-2 below, was used to estimate the dermally absorbed dose (DA_{event}, mg/cm²) for an absorption event occurring over a defined duration 835 836 (t_{abs}).

837

839


838 **Equation 2-2. Dermal Absorption Dose During Absorption Event**

$$DA_{event} = 2 \times FA \times K_p \times S_W \times \sqrt{\frac{6 \times t_{lag} \times t_{abs}}{\pi}}$$

840 Where.

040	WIELE.		
841	$DA_{event} =$	Derm	ally absorbed dose during absorption event t _{abs} (mg/cm ²)
842	FA	=	Effect of stratum corneum on quantity absorbed = 0.9 [see Exhibit A-5 of
843			U.S. EPA (<u>2004</u>)]
844	K_p	=	Permeability coefficient = 0.012 cm/h (calculated using CEM (<u>U.S. EPA</u> ,
845			<u>2023</u>))
846	S_w	=	Water solubility = 1.48 mg/L [see Table Apx B-1 in <i>Draft Physical</i>
847			Chemistry and Fate and Transport Assessment for Dicyclohexyl Phthalate
848			(DCHP) (<u>U.S. EPA, 2024e</u>)
849	t_{lag}	=	$0.105 \times 10^{0.0056 \text{MW}} = 0.105 \times 10^{0.0056 \times 330.43} = 7.44$ hours [calculated from A.4]
850			of U.S. EPA (<u>2004</u>)]
851	t_{abs}	=	Duration of absorption event (hours)
852			

853 By dividing the dermally absorbed dose (DA_{event}) by the duration of absorption (t_{abs}), the resulting 854 expression yields the average absorptive flux. Figure 2-2 illustrates the relationship between the average 855 absorptive flux and the absorption time for DCHP.



857

858 Figure 2-2. DCHP Average Absorptive Flux vs. Absorption Time

859

860 The neat form of DCHP is a solid, the concentrated formulations are paste-like, and any liquid 861 containing DCHP has very low concentrations; therefore, it is reasonable to assume that flux-limited 862 absorption of aqueous DCHP serves as a reasonable upper bound for the dermal absorption of DCHP 863 across consumer scenarios. Dermal exposure to DCHP from solid articles is estimated using a flux-864 based approach. In this approach it was assumed that DCHP must first migrate into a thin film of 865 moisture on the surface of the skin, and that solubility of DCHP by the moisture layer limits absorption. The flux-limited approach was used for both liquid and solid products. Aqueous flux-limited absorption 866 values ranged from 1.19×10^{-4} to 2.43 mg/cm²/h for 1 to 24 hours, see Figure 2-2. The estimation of 867 average flux of aqueous material through and into the skin is dependent on the duration of absorption 868 and must be determined based on the scenario under assessment. The 1 to 24 hours absorption time 869 870 range captures the dermal exposure scenarios duration used in consumer scenarios. The dermal 871 consumer exposure assessment scenarios consider a range of exposure durations that capture low, medium, and high intensity use scenarios and are described for each COU and product/article scenario in 872 Section 2.3.3. 873

874

2.3.3 Modeling Inputs and Parameterization

875 Key parameters for the dermal model include duration of dermal contact, frequency of dermal contact, 876 total contact area, and dermal flux; an increase in any of these parameters results in an increase in exposure. Key parameter values used in models are shown in Table 2-9. For contact area, professional 877 878 judgement, based on product use descriptions from manufacturers and article typical use, was applied to 879 determine reasonable contact areas for each product or article. In addition to considering typical product 880 and article use, EPA used conservative contact area options with the possibility of further refining the scenario should risk be identified in Section 4 of the Draft Risk Evaluation for Dicyclohexyl Phthalate 881 882 (DCHP) (U.S. EPA, 2024f). The subsections under Table 2-9 provide details on assumptions used to 883 derive other key parameters. Calculations, sources, input parameters and results are also available in 884 Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP) - Supplemental Information File: Consumer 885 *Exposure Analysis* (U.S. EPA, 2024a). Acute and chronic dose calculations and equations are

summarized in Appendix A.4.

887 888

|--|

Product	Scenario	Duration of Contact (min)	Chronic Frequency of Contact (year ⁻¹)	Acute Frequenc y of Contact (day ⁻¹)	Flux ^{<i>a</i>} (mg/cm ² /h)	Contact Area	
A	High	60			1.21E-04		
Adhesives for Small	Medium	30	52	1	1.70E-04	10% of Hands (some fingers)	
Repairs	Low	15			2.41E-04		
	High	120	2	1	8.52E-05		
Automotive Adhesives	Medium	60			1.21E-04	10% of Hands (some fingers)	
	Low	30			1.70E-04		
	High	137	365	1	7.97E-05	Inside of two hands (palms, fingers)	
Children's Toys	Medium	88			9.95E-05		
	Low	24			1.91E-04		
	High	240			6.03E-05		
Outdoor Seating	Medium	120	52	1	8.52E-05	Inside of two hands (palms, fingers)	
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Low	60			1.21E-04	(pullis, ingets)	
Small Articles with Potential for semi-routine contact	High	120	365			8.52E-05	
	Medium	60		1	1.21E-04	Inside of one hand (palms, fingers)	
	Low	30			1.70E-04	- (panns, imgers)	

^{*a*} See Section 2.3.2 and *Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP) - Supplemental Information File: Consumer Exposure Analysis* (U.S. EPA, 2024a).

889

# 890 Duration of Use/Article Contact Time

For liquid and paste products, it was assumed that contact with the product occurs at the beginning of the period of use and the product is not washed off until use is complete. As such, the duration of dermal contact for these products is equal to the duration of use applied in CEM modeling for products. For products not modeled in CEM (adhesives for small repairs), it was assumed that use would be relatively quick, though project size may vary. As such, durations for high, medium, and low exposure scenarios were assumed to be 60, 30, and 15 minutes.

897

898 For articles that do not include duration of use as an input in CEM, professional judgement was used to

select the duration of use/article contact for the low, medium, and high exposure scenario levels. For
children's toys, data was obtained from the Children's Exposure Factors Handbook, Table 16-26.

Reported values for playtime for children under 15 years ranged from 24 min/day to 137 min/day, with a

902 mean value of 88 min/day; these values were used in the low, high, and medium exposure scenarios. The

903 playtime duration used for children under 15 years was also used for children 16 to 20 years due to lack 904 of playtime duration information for this age range and as conservative assumption that can be further 905 refined should risk be identified in the risk characterization stage of this assessment; see Section 4 of the 906 *Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP)* (U.S. EPA, 2024f). For concrete coatings on 907 outdoor seating, a maximum duration of 240 minutes was selected to represent attendance of sporting 908 events. Shorter durations of 120 and 60 minutes were selected for medium and low scenarios to 909 represent shorter events.

910

911 In addition to the scenarios for dermal exposure to DCHP from specific articles, a scenario was modeled 912 in which consumers may have semi-routine contact with one or more small items containing DCHP. An 913 outline of materials which might be captured in this scenario is provided in Section 2.1. While dermal 914 contact with individual items is expected to be short and/or irregular in occurrence, use of these articles 915 is not well documented, and there is likely to be significant variability in use patterns between individual 916 consumers. However, given the uncertainty around items with DCHP content, EPA considers it 917 reasonable to assume that an individual could have significant daily contact with some combination of 918 items and/or with other similar items that have not been measured during monitoring campaigns. As such, articles modeled under this scenario were assumed to have dermal contact times of 120, 60, and 30

- 919 such, articles modeled under this scenario were assumed to have dermal contact times of 120, 60, and 30 920 minutes per day.
- 921
- 922 Frequency of Use

For liquid and paste products modeled in CEM, frequency of contact was assumed to be equal to the frequency of use (per year and per day) that was applied in CEM modeling. For adhesives used for small repairs and projects, it was assumed that individuals might be in contact once per week.

926

For articles, assumptions about frequency of use were made based on professional judgement based on one contact per event duration as a conservative screening approach, further refinement is considered at

928 one contact per event duration as a conservative screening approach, further refinement is considered a 929 the risk calculation stage, see *Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP)* (U.S. EPA,

2024f). For articles which are expected to be used on a routine basis, such as children's toys, and small

articles with semi-routine contact potential, use was assumed to be once per day every day. For concrete

932 coatings used on outdoor seating, it was assumed that an event was attended once per week.

933

# 2.4 Key Parameters for Intermediate Exposures

The intermediate doses were calculated from the average daily dose, ADD, (µg/kg-day) CEM output for
that product using the same inputs summarized in Table 2-8 for inhalation and Table 2-9 for dermal.
EPA used professional judgment based on manufacturer and online product use descriptions to estimate
events per day and per month for the calculation of the intermediate dose, see Appendix 7A.3

938

# 939 Table 2-10. Short-Term Event per Month and Day Inputs

Product	Events Per Day ^a	Events Per Month ^a
Construction Adhesive for Small Scale Projects	3	4
Construction Sealant for Large Scale Projects	1	3
Lacquer Sealer (Non-spray)	1	2
Lacquer Sealer (Spray)	1	2
^{<i>a</i>} Events per day and month values determined using professional judg description use.	ement based on manuf	acturer product

# 941 **3 CONSUMER EXPOSURE MODELING RESULTS**

This section summarizes the dose estimates from inhalation, ingestion, and dermal exposure to DCHP in consumer products and articles. Exposure via the inhalation route occurs from inhalation of DCHP gasphase emissions or when DCHP partitions to suspended particulate from direct use or application, or installation of products and articles. Exposure via the dermal route occurs from direct contact with products and articles. Exposure via ingestion depends on the product or article use patterns. It can occur via direct mouthing (*i.e.*, directly putting an article in mouth) or ingestion of suspended and/or settled dust when DCHP migrates from a product or article to dust or partitions from gas-phase to dust.

# 949 **3.1** Acute Dose Rate Results, Data, Patterns, and Conclusions

The DCHP Draft Consumer Risk Calculator (U.S. EPA, 2024c) summarizes all the high, medium, and 950 low acute dose rate results for all lifestages from CEM modeling for inhalation and ingestion exposures, 951 952 and computational modeling for all dermal exposures. Products and articles marked with a dash (-) did 953 not have dose results because the product or article was not evaluated quantitatively, see Section 2.1 for 954 discussion about qualitative assessments and rationale for not evaluating certain exposure routes. Dose 955 results applicable to bystanders are highlighted. Bystanders are people that are not in direct use or 956 application of a product but can be exposed to DCHP by proximity to the use of the product via 957 inhalation of gas-phase emissions or suspended dust. Some product scenarios were assessed for 958 bystanders for children under 10 years and as users older than 11 years because the products were not 959 targeted for very young children (<10 years). In instances where a lifestage could reasonably be either a 960 product user or bystander, the inputs for a user were selected because that scenario would result in larger 961 exposure doses as compared to a bystander. The main purpose of *Draft Consumer Risk Calculator* 962 (DCHP) (U.S. EPA, 2024c) is to summarize acute dose rate results (and risk estimates), show both 963 which products or articles did not have a quantitative result and which results are used for bystanders. 964 Data patterns are illustrated in figures in this section with a summary and descriptions of the patterns by 965 exposure route and population or lifestage.

966

Figure 3-1 through Figure 3-4 show acute dose rate data for all products and articles modeled for all
lifestages. The figures show average dose rate (ADR) estimated from exposure via inhalation, ingestion
(aggregate of mouthing, suspended dust ingestion, and settled dust ingestion), and dermal contact.
Among the younger lifestages (*i.e.*, <5 years), exposures are driven by ingestion via mouthing, while</li>
inhalation and dermal patterns are similar to other lifestages for these same exposure pathways. For
children older than 6 years, teens, and adults, dermal contact was a strong driver of exposure to DCHP—
higher than the dose received from exposure via inhalation or ingestion.

974

975 The spread of values estimated for each product or article reflects the aggregate effects of variability and 976 uncertainty in key modeling parameters for each item. Acute dose rate for some products/articles covers 977 a larger range than others primarily due to a wider distribution of DCHP weight fraction values, 978 chemical migration rates for mouthing exposures, and behavioral factors such as duration of use or 979 contact time and mass of product used as described in Section 2.2.3. Key differences in exposures 980 among lifestages include designation as a product user or bystander; behavioral differences such as 981 mouthing durations, hand to mouth contact times, and time spent on the floor; and dermal contact 982 expected from touching specific articles, which may not be appropriate for some lifestages. Figures and 983 observations specific to each lifestage are below.

984

Of all scenarios evaluated, for all products and articles, and all lifestages (see Figure 3-2 to Figure 3-4),
infants, toddlers, and preschoolers have the highest dose of DCHP from a single exposure route.
Specifically, this is due to the DCHP dose from ingestion of settled and suspended dust and direct

mouthing. For articles assessed for mouthing, such as toys, exposure from mouthing is expected to have

- a larger impact in the overall ingestion dose compared to ingestion of settled and suspended dust.
- 990 Mouthing tendencies decrease or cease entirely for children 6 to 10 years old (Figure 3-2). Articles that
- were not assessed for mouthing were assessed for ingestion of settled and suspended dust, for which the
- settled dust exposures tend to be larger than ingestion from suspended dust (*Draft Consumer Risk Calculator (DCHP)* (U.S. EPA, 2024c)).
- 994

# 995 Infants, Toddlers, and Preschoolers, (Birth to 5 Years)

Figure 3-1 show all exposure routes for infants less than one year old, toddlers 1 to 2 years old, and
preschoolers 3 to 5 years old. Dose result patterns were very similar for the same products or articles and
routes of exposure across these three lifestages, see *Draft Consumer Risk Calculator (DCHP)* (U.S.
<u>EPA, 2024c</u>). EPA averaged the three lifestages into one dose result for all in Figure 3-1. Acute dose for
the ingestion route is the sum of all ingestion scenarios (mouthing, suspended dust, and surface dust).
Inhalation exposure from toys considers dust collected on surfaces and settled dust from a relatively
large area that contains multiple toys collecting dust with DCHP.

1002

1004 For infants through 5-year-olds, ingestion resulted in the highest ADR followed by the dermal and then 1005 inhalation routes. The ingestion ADR for high and medium intensity use are higher than the full range of 1006 the dermal ADR values for all items, while the ingestion low intensity ADR is three orders of magnitude 1007 lower than the dermal low intensity ADR. Dermal exposure differences among items and high to low 1008 intensity use scenarios are driven mainly by the exposure duration and frequency, and exposed dermal 1009 surface area. The dose from coated outdoor seating and children's toys were similar and about an order of magnitude higher than for articles with potential for semi-routine contact mainly due to longer contact 1010 1011 durations and frequencies. Notably, the contact duration (see Table 2-9) for coated outdoor seating was 1012 longer than that for children playing with toys. The outdoor seating high to low intensity use scenarios 1013 considered plausible ranges of outdoor activities like sporting events and concerts, and plausible skin 1014 contact area; however, EPA recognizes that continuous contact for the duration of the event may be an 1015 overestimation. The children's toys scenario considers total contact duration in one day with single toys 1016 rather than assuming frequency (how many times a child plays with a toy in a day) of contact in a day 1017 with a single toy, which would have introduced larger uncertainty to the ADR calculation. See Table 2-9 1018 for dermal modeling parameters per products and articles.

1019


1020 Inhalation doses of automotive adhesives for the infant, toddler, and preschooler lifestages represent

1021 bystander exposures because these lifestages are not expected to be users of these product types. The 1022 inhalation doses from automotive adhesive products are overall higher than the inhalation doses from

1022 innatation doses from automotive adhesive products are overall higher than the inhalation doses from 1023 indeer inhelation of suspended dust from shildren's toys. The differences are driven by increased DCHP

1023 indoor inhalation of suspended dust from children's toys. The differences are driven by increased DCHP

weight fractions in automotive adhesives (see Table 2-8) as compared to children's toys (see Table 2-5).



### 1026

1031

# 1027Figure 3-1. Acute Dose Rate for DCHP from Ingestion, Inhalation, and Dermal Exposure Routes1028in Infants Aged <1 Year, Toddlers Aged 1–2 Years, and Preschoolers Aged 2–5 Years</td>

1029 Note: Preliminary figure, horizontal axis label is for infants, toddlers, and preschoolers. Cutoff vertical label is for 1030 articles with potential for semi-routine contact.

# 1032 Middle Childhood, Young Teens, Teenagers, Young Adults, and Adults (6–21 and >21 Years)

1033 Figure 3-2 through Figure 3-4 show all exposure routes for children ages 6 to adults above 21 years old. 1034 Dose result patterns were very similar for the same products or articles and routes of exposure across 1035 these five lifestages; see Draft Consumer Risk Calculator (DCHP) (U.S. EPA, 2024c) doses per 1036 lifestage. However, because some products were not targeted for all lifestages, EPA only averaged the 1037 lifestages ADR values when the lifestages considered the same products and articles into one dose result 1038 for all in Figure 3-2 through Figure 3-4. Children 6 to 10 years old Figure 3-2 and adults older than 21 1039 years, Figure 3-4, stand alone because children 6 to 10 years are not targeted to use or have bystander 1040 exposures from automotive adhesives and adhesives for small repairs and adults lack dermal exposures to toys. Children 11 to 15 years and teenagers and young adults aged 16 to 20 years were averaged 1041 1042 because the ADR results were comparable and the same products and articles were assessed for these 1043 two lifestages in Figure 3-3.

1044

The ADR for the inhalation and ingestion exposure routes cover a larger range, see high to low intensity
use ADR values, than the dermal route for the same product and article categories such as for adhesives.
This wider range for inhalation and ingestion ADR values is primarily due to a wider distribution of
weight fraction (see Table 2-5 and Table 2-8) values. Weight fraction inputs are used in the ingestion
and inhalation ADR CEM modeling, but not in the dermal calculations.

1050

1051 For all lifestages from age 6 through adult, the ADR from the dermal exposure route represents the 1052 highest dose, followed by the inhalation and ingestion routes, for all articles and products. Dermal 1053 exposure differences among article and product scenarios are driven mainly by the exposure duration 1054 and frequency and exposed skin surface area. Dermal exposure resulted in the highest doses overall. Coated outdoor seating dermal doses are similar to children's toys, then articles with potential for semi-1055 1056 routine contact, and finally the adhesive products. The contact duration for toys is slightly shifted than 1057 for outside seating; thus, dermal doses from exposure to toys and outside seating are considered similar. Dermal doses from exposure to children's toys are similar for all lifestages from 6 to 20 years (see 1058 1059 Figure 3-1 to Figure 3-3). The playtime duration used for children under 15 was also used for children 16 to 20 years due to lack of playtime duration information for this age group and as conservative 1060 assumption that can be further refined should risk be identified in the risk characterization stage of this 1061 1062 draft assessment; see Section 4 of the Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP) (U.S. EPA, 2024f). Dermal doses for articles with potential for semi-routine contact are larger than for 1063 adhesives mainly due to differences in exposure duration per event and a smaller surface area in contact. 1064


Inhalation exposure as a bystander for lifestages above 10 years of age was not targeted for adhesives
and sealants. Children above 10 years can use these products in a similar capacity as adults during do-ityourself (DIY) projects and as bystanders; therefore, this lifestage was modeled as a user of the product
rather than a bystander. Users and bystanders have similar inhalation exposure doses for automotive
adhesives. Inhalation of suspended dust from toys is similar across lifestages.

1071

Ingestion via mouthing is significantly lower which is expected due to a decrease or cessation in
 mouthing behavior. Mouthing tendencies decrease significantly for theses lifestages; thus, most
 scenarios do not estimate exposure via mouthing. Ingestion of settled dust is the only ingestion pathway
 considered outside of mouthing for children's toys, which suggests that indoor dust ingestion and

1075 considered outside of mouthing for children's toys, which suggests that indoor dust ingestion and
 1076 inhalation from dust collected on children's toys can contribute to DCHP exposures. However, these are
 1077 multiple orders of magnitude lower than dermal exposures.

1078




1079

# Figure 3-2. Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for Middle Childhood Ages 6–10 Years

1082 Note: Cutoff vertical axis label is for articles with potential for semi-routine contact. Figure will be corrected in1083 the finalized risk evaluation.


1084 1085



1086

Figure 3-3 Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes for
 Young Teens Aged 11–15 Years and Teenagers and Young Adults Aged 16–20 Years

1089 Note: Horizontal axis label is for young teens, teenagers, and young adults. Cutoff vertical label is for articles
 1090 with potential for semi-routine contact. Figure will be corrected in the finalized risk evaluation.



1091

# 1092Figure 3-4. Acute Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure Routes in1093Adults Older than 21 Years

1094 Note: Cutoff vertical axis label is for articles with potential for semi-routine contact. Figure will be corrected in1095 the finalized risk evaluation.

# 1096 **3.2 Intermediate Average Daily Dose Conclusions and Data Patterns**

The Draft Consumer Risk Calculator (DCHP) (U.S. EPA, 2024c) summarizes all the intermediate dose 1097 1098 results for high (H), medium (M), and low (L) intensity use scenarios based on modeling in CEM and 1099 outside of CEM (dermal only) for all exposure routes and lifestages. Only one product example under the Adhesives and sealants COU was a candidate for intermediate exposure scenarios. Intermediate 1100 exposure scenarios were built for products used between 30 and 60 days, and EPA used 30 days or 1101 1102 approximately 1 month for product use. Some products did not have dose results because the product 1103 examples were not targeted for that lifestage for that exposure route. Scenarios without dose results are 1104 marked with a dash (-).

1105


Only automotive adhesives qualified to be used in intermediate scenarios. Based on manufacturer use description and professional judgement/assumption, these products may be used repeatedly within a 30day period depending on projects. Infants to middle childhood lifestages do not have dermal doses as these products are not targeted for their use and application. However, starting from young teens through adults, it is possible that these lifestages can use automotive and construction adhesives in home renovation projects or other hobbies. Infants to middle childhood lifestages are considered bystanders when these products are in use and are exposed via inhalation. Direct dermal contact has a larger dose

- 1113 than inhalation for the uses during application. See Figure 3-5 and Figure 3-6 for intermediate dose
- 1114 visual representations.
- 1115



# Figure 3-5. Intermediate Dose Rate for DCHP from Inhalation Exposure Route in Infants Aged <1</li> Year to Middle Childhood Aged 6–10 Years

1119 Note: Horizontal axis label is for infants, toddlers, preschoolers, and middle childhood. Figure will be corrected in 1120 the finalized risk evaluation.



## 1122

## 1123 Figure 3-6. Intermediate Dose Rate for DCHP from Inhalation Exposure Route Young Teens


1124 Aged 11–15 Years to Adults Older than 21 Years

1125 Note: Horizontal axis label is for young teens, teenagers, young adults, and adults. Figure will be corrected in the 1126 finalized risk evaluation.

# 1127 **3.3 Non-cancer Chronic Dose Results, Data Patterns, and Conclusions**


1128 The Draft Consumer Risk Calculator (DCHP) (U.S. EPA, 2024c) summarizes all the high (H), medium 1129 (M), and low (L) intensity use chronic daily dose results from modeling in CEM and outside of CEM 1130 (dermal only) for all exposure routes and all lifestages. Some products and articles did not have dose 1131 results because the product or article was not targeted for that lifestage or exposure route. Scenarios 1132 without dose results are marked with a dash (-). Dose results applicable to bystanders are highlighted in 1133 yellow. Bystanders are people that are not in direct use or application of the product/article but can be exposed to DCHP by proximity to the use of the product/article via inhalation of gas-phase emissions or 1134 1135 suspended dust. Some product/article scenarios were assessed for bystanders for children under 10 years 1136 and as users for older than 11 years because the products were not targeted for very young children (<10 yrs). People older than 11 years can also be bystanders; however, the user scenarios had inputs that 1137 1138 would result in larger exposure doses. The main purpose of Draft Consumer Risk Calculator (DCHP) 1139 (U.S. EPA, 2024c) is to summarize chronic daily dose results (and risk estimates), show which products 1140 or articles did not have a quantitative result, and which results are used for bystanders.

- 1141 1142 Data patterns are illustrated in figures and summary descriptions of the patterns by exposure route and population or lifestage are summarized in this section. The following set of figures (see Figure 3-7 to 1143 1144 Figure 3-10) show chronic average daily dose data for all products and articles modeled in all lifestages. 1145 For each lifestage, figures are provided which show CADD estimated from exposure via inhalation, 1146 ingestion (aggregate of mouthing, suspended dust ingestion, and settled dust ingestion), and dermal 1147 contact. The chronic average daily dose figures resulted in similar overall data patterns as the acute 1148 doses for inhalation and ingestion, but not dermal exposures. Outdoor seating dermal doses are lower for 1149 chronic because the frequency of use is less throughout a year (*i.e.*, once a week in a year), while contact 1150 with children's toys is the largest dermal dose because the frequency of contact is every day for a year. 1151 Articles with potential for routine contact dermal dose is larger than outside seating because frequency 1152 of contact is larger per year, but smaller than the dermal doses from toys due to smaller use durations per 1153 event. See Table 2-9 for dermal modeling parameters per scenario.
- 1154



### 1169

- 1170 1171 for Young Teens Aged 11-15 Years and Teenagers and Young Adults Aged 16-20 Years
- 1172 Note: Horizontal axis label is for young teens, teenagers, and young adults. Cutoff vertical label is for articles
- 1173 with potential for semi-routine contact. Figure will be corrected in the finalized risk evaluation.
- 1174



#### 1175

## 1176 Figure 3-10. Chronic Dose Rate of DCHP from Ingestion, Inhalation, and Dermal Exposure

- 1177 Routes in Adults Older than 21 Years
- 1178 Note: Cutoff vertical axis label is for articles with potential for semi-routine contact. Figure will be corrected in
- 1179 the finalized risk evaluation.

# 1180 4 INDOOR DUST MODELING AND MONITORING COMPARISON

In this indoor dust exposure assessment, EPA compared modeling and monitoring data. Modeling data 1181 used in this comparison originated from the consumer exposure assessment, Table 2-1, to reconstruct 1182 major indoor sources of DCHP in dust and obtain COU and product specific exposure estimates for 1183 1184 ingestion and inhalation of dust. Other non-residential environments can have these articles, such as daycares, offices, malls, schools, and other public indoor spaces. The indoor consumer articles exposure 1185 scenarios were modeled with stay-at-home parameters that consider use patterns similar or higher than 1186 1187 those in other indoor environments. Therefore, EPA concludes that exposures to similar articles in other 1188 indoor environments are included in the residential assessment as a health protective upper-bound 1189 scenario.

1190

The monitoring data considered are from residential dust samples from U.S.-based studies. Measured DCHP concentrations were compared to evaluate consistency among data sets. EPA used three U.S. monitoring studies to generate an estimate of overall DCHP exposure from ingestion of indoor dust but a monitoring and modelling comparison was not performed due to low confidence in the monitoring data as an adequate U.S. population representative. The monitoring studies and assumptions made to estimate

1196 exposure are described in Section 4.1 and Section 4.2.

# 1197**4.1 Indoor Dust Monitoring Data**

1198 During systematic review, a total of 13 studies containing potential indoor dust monitoring data for 1199 DCHP were identified. Data from the U.S. and multiple Asian and European countries were identified. 1200 Out of these studies, three were selected because they are primary studies conducted in the United States, reported sampling and analytical methods, and measured dust in a home, offices, or other indoor 1201 1202 environments that are representative of the U.S. general population. Data from other countries, such as China, India, Kuwait, Vietnam, and Turkey, were not included in the comparison because of the 1203 expected difference in use patterns, behaviors, and residential characteristics as compared to the U.S. 1204 1205 population. Data from German studies would be an acceptable surrogate, but the reported data is mainly 1206 from non-residential locations or targeting non-TSCA sources such as personal care products. 1207

In <u>Rudel et al. (2001)</u>, six settled dust samples were collected from the United States. One sample was
from an office and five samples were from three different homes in the living areas, attic, and basement.
The study does not report the year of the samples taken. Samples were collected by slowly and lightly
drawing a vacuum crevice tool just above the surface of rugs, upholstery, wood floors, windowsills,
ceiling fans, and furniture in each room for 45 to 90 minutes.

1213

In <u>Guo and Kannan (2011)</u>, 33 settled dust samples were collected from Albany, New York, between
December 2007 and January 2008, as well as during May 2010. Samples contained particles from carpet
flooring and were taken by vacuum cleaner bags of several homes.

1217 1218 In

In <u>Dodson et al. (2015)</u>, 49 settled dust samples were collected from homes in California during 2006.
Samples were collected by slowly dragging a vacuum crevice tool just above the surface of rugs,
upholstery, wood floors, windowsills, ceiling fans, and furniture in the primary living areas of the home
for about 30 minutes.

- 1222
- 1223 DCHP measurements from the three studies are provided in Table 4-1.
- 1224

#### Table 4-1. Detection and Quantification of DCHP in House Dust from Three Studies 1225

Study	Indoor Environment ^a	N	Mean (µg/g)	Median (µg/g)	Min (µg/g)	Max (µg/g)	SD (µg/g)	95th Percentile (µg/g)	Detection Frequency (%)
<u>Rudel et al.</u> (2001)	Combined	6	1.86 ^b	$\mathbf{NR}^{c}$	0.569	5.38	1.62	NR	100
<u>Guo and</u> Kannan (2011)	Home	33	NR	$ND^d$	ND	0.3	NR	NR	18
<u>Dodson et al.</u> (2015)	Home	49	NR	ND	ND	13	NR	7.4 ^b	16
^a Combined refers to multiple indoor environments including household living areas, attic, basement, and an office									

building.

^b Used in dust ingestion calculations for central tendency (mean) and high-end tendency (95th percentile). Equation 4-1 ^c NR, not reported.

¹ND, not detected.

1226

1227 Available DCHP dust monitoring data is very limited, and therefore has limitations in terms of its

representativeness of actual dust concentrations in U.S. homes. Given the unknown effects of the 1228

- identified uncertainties within the monitoring data, EPA calculated the ingestion doses (Section 4.2) 1229
- 1230 from monitoring data but no further analysis or use of the monitoring data should be expected in this
- 1231 assessment.

# 4.2 Indoor Dust Monitoring Ingestion Dose Results

1233 To estimate DCHP dust ingestion, the mean ingestion from the measured concentrations for residential 1234 (homes) in Table 4-1 was used (see table note b). Studies that did not report means were not used in the 1235 calculation and only residential values were used. The same equation was used to calculate the 95th 1236 percentile.

1237

1232

1238 EPA obtained U.S. sources for dust ingestion rate and body weights to conduct allometric exposure 1239 estimates. In their study, Özkaynak et al. (2022) parameterized the Stochastic Human Exposure Dose 1240 Simulation (SHEDS) Model to estimate dust and soil ingestion for children ages 0 to 21 years old with 1241 U.S. data, including the Consolidated Human Activity Database (CHAD) diaries. This most recent 1242 version incorporates new data for young children including pacifier and blanket use, which is important 1243 because dust and soil ingestion is higher in young children relative to older children and adults. 1244 Geometric mean and 95th percentile dust ingestion rates for ages 0 to 21 years were taken from Özkaynak et al. (2022) to estimate DCHP ingestion dose in dust (Table 4-2). The geometric mean was 1245 used as the measure of central tendency because the distribution of ingestion intakes is skewed. 1246

1247 1248 Özkaynak et al. (2022) did not estimate dust ingestion rates for ages beyond 21 years. However, the 1249 *Exposure Factors Handbook* (U.S. EPA, 2011a) does not differentiate dust or soil ingestion beyond 12 1250 years old (U.S. EPA, 2017). Therefore, ingestion rates for 16 to 21 years, the highest age range 1251 estimated in Özkaynak et al. (2022), were used for ages beyond 21 years. Using body weight estimates 1252 from the Handbook, estimates were calculated for DCHP ingestion doses for 21 to 80 or more years (Table 4-3).

- 1253
- 1254

1255 DCHP dust ingestion was calculated according to Equation 4-1 for two scenarios, (1) mean (geometric

1256 mean [GM] dust inhalation, median DCHP concentration in dust); and (2) high-end (dust inhalation, 1257 95th percentile DCHP concentration in dust). The mean from Rudel et al. (2001) and 95th percentile

- 1258 from Dodson et al. (2015) were used in the calculation for DCHP ingestion dose. Body weights
- 1259 representative of the U.S. population were taken from the *Exposure Factors Handbook* (U.S. EPA,

1260 <u>2011b</u>).

#### 1261

## 1262 Equation 4-1. Calculation of DCHP Ingestion Dose

1263  $DCHP \ dose \ \left(\frac{\mu g \ DCHP}{kg \ bw \times day}\right) = \frac{Dust \ ingestion \ \left(\frac{mg \ dust}{day}\right) \times Dust \ concentration \ \left(\frac{\mu g \ DCHP}{g \ dust}\right)}{kg \ bw} \times \frac{1 \ g}{1000 \ mg}$ 1264

1265 Estimates of DCHP ingestion in indoor dust per day based on monitoring data are presented in Table 4-21266 and Table 4-3.

1267

## 1268 Table 4-2. Estimates of DCHP Dust Ingestion Per Day from Monitoring, Ages 0–21 Years

Age R	ange	0-<1 m	1-<3 m	3-<6 m	6 m-<1 y	1-<2 y	2-<3 y	3-<6 y	6-<11 y	11-<16 y	16-<21 y
Dust	GM	3.6	3.5	4.1	5.4	8	8.9	10	12	15	16
ingestion (mg/day) ^{<i>a</i>}	95th Percentile	7.1	5.8	6.1	8.0	13	14	14	17	22	25
Body weight	t (kg) ^b	4.8	4.8	5.9	7.4	9.2	11	14	19	32	57
DCHP Ingestion	Central tendency (1.86 µg DCHP/g dust)	5.6E-3	4.4E-3	4.1E-3	4.3E-3	5.2E-3	4.8E-3	4.0E-3	2.8E-3	2.0E-3	5.6E-3
(μg/kg-day)	High end (7.4 µg DCHP/g dust)	5.6E-3	4.4E-3	4.1E-3	4.3E-3	5.2E-3	4.8E-3	4.0E-3	2.8E-3	2.0E-3	1.7E-3
m = month(s) ^a From <u>Özka</u> ^b From <u>U.S.</u>	ynak et al. (	(2022)									

1269

1270 1271

## Table 4-3. Estimates of DCHP Dust Ingestion Per Day from Monitoring, Ages 21–80+ Years

Age l	Range	21-<30 y	30-<40 y	40–<50 y	50-<60 y	60-<70 y	70-<80 y	>80 y
Dust	GM	16	16	16	16	14	13	12
ingestion (mg/day) ^a	95th Percentile	21	21	21	21	18	17	16
DCHP Ingestion (µg/kg-day)	Central tendency (1.86 µg DCHP/g dust)	1.7E-3	1.5E-3	1.5E-3	1.4E-3	1.4E-3	1.3E-3	1.2E-3
	High end (7.4 µg DCHP/g dust)	1.5E-3	1.5E-3	1.4E-3	1.4E-3	1.3E-3	1.2E-3	1.3E-3
Body weight (kg) ^b		78	78	81	84	83.4	82.6	76.4
	ynak et al. (2 EPA (2011b)	022) (rates for	16-21y)					

1272 1273

# 1274 **5 WEIGHT OF SCIENTIFIC EVIDENCE**

## 1275

## 5.1 Consumer Exposure Analysis Weight of Scientific Evidence

1276 Variability refers to the inherent heterogeneity or diversity of data in an assessment. It is a description of 1277 the range or spread of a set of values. Uncertainty refers to a lack of data or an incomplete understanding 1278 of the context of the risk evaluation decision. Variability cannot be reduced, but it can be better 1279 characterized. Uncertainty can be reduced by collecting more or better data. Uncertainty is addressed 1280 qualitatively by including a discussion of factors such as data gaps and subjective decisions, or instances 1281 where professional judgment was used. Uncertainties associated with approaches and data used in the 1282 evaluation of consumer exposures are described below.

1283

The exposure assessment of chemicals from consumer products and articles has inherent challenges due to many sources of uncertainty in the analysis, including variations in product formulation, patterns of consumer use, frequency, duration, and application methods. Variability in environmental conditions may also alter physical and/or chemical behavior of the product or article. Key sources of uncertainty for evaluating exposure to DCHP in consumer goods and strategies to address those uncertainties are described in this section.

1290

1291 Generally, designation of robust confidence suggests thorough understanding of the scientific evidence 1292 and uncertainties. The supporting scientific evidence outweighs the uncertainties to the point where it is 1293 unlikely that the uncertainties could have a significant effect on the exposure estimate. The designation 1294 of moderate confidence suggests some understanding of the scientific evidence and uncertainties. More 1295 specifically, the supporting scientific evidence weighed against the uncertainties is reasonably adequate 1296 to characterize exposure estimates. The designation of slight confidence is assigned when the weight of 1297 scientific evidence may not be adequate to characterize the scenario, and when the assessor is making 1298 the best scientific assessment possible in the absence of complete information and there are additional 1299 uncertainties that may need to be considered. Table 5-1 summarizes the overall uncertainty per COU, 1300 and a discussion of rationale used to assign the overall uncertainty. The subsections ahead of the table 1301 describe sources of uncertainty for several parameters used in consumer exposure modeling that apply 1302 across COUs and provide an in depth understanding of sources of uncertainty and limitations and 1303 strengths within the analysis. The confidence to use the results for risk characterization ranges from 1304 moderate to robust, see Table 5-1. The basis for the moderate to robust confidence in the overall 1305 exposure estimates is a balance between using parameters that represent various populations, use 1306 patterns, and lean on protective assumptions that are not outliers, excessive, or unreasonable.

1307

## 1308 Product Formulation and Composition

1309 Variability in the formulation of consumer products, including changes in ingredients, concentrations, 1310 and chemical forms, can introduce uncertainty in exposure assessments. In addition, data were limited for weight fractions of DCHP in consumer goods. EPA obtained DCHP weight fractions in various 1311 1312 products and articles from material safety sheets, databases, and existing literature (Section 2.1). Where 1313 possible, EPA obtained multiple values for weight fractions for similar products or articles. The lowest 1314 value was used in the low exposure scenario, the highest value in the high exposure scenario, and the 1315 average of all values in the medium exposure scenario. EPA decreased uncertainty in exposure and 1316 subsequent risk estimates in the high, medium, and low intensity use scenarios by capturing the weight 1317 fraction variability and obtaining a better characterization of the products and articles varying 1318 composition within one COU. Overall weight fraction confidence is **moderate** for products/articles with 1319 only one source, **robust** for products/articles with more than one source and **slight** for articles with only

1321

## 1322 Product Use Patterns

1323 Consumer use patterns like frequency of use, duration of use, and methods of application are expected to

differ. Where possible, high, medium, and low default values from CEM 3.2's prepopulated scenarios

1325 were selected for mass of product used, duration of use, and frequency of use. In instances where no

1326 prepopulated scenario was appropriate for a specific product, low, medium, and high values for each of

- these parameters were estimated based on the manufacturers' product descriptions. EPA decreased
- uncertainty by selecting use pattern inputs that represent product and article use descriptions and
   furthermore capture the range of possible use patterns in the high to low intensity use scenarios.
- 1330 Exposure and risk estimates are considered representative of product use patterns and well characterized.
- 1331 Most use patterns' overall confidence is rated **robust**.

## 1332

## 1333 Article Surface Area

1334 The surface area of an article directly affects the potential for DCHP emissions to the environment. For

each article modeled for inhalation exposure, low, medium, and high estimates for surface area were calculated (Section 2.2.3.1). For small items which might be expected to be present in a home in

calculated (Section 2.2.3.1). For small items which might be expected to be present in a home insignificant quantities, such as children's toys, multiple items of the same type were aggregated to

significant quantities, such as children's toys, multiple items of the same type were aggregated tocalculate the cumulative surface area for each type of article in the indoor environment. Overall,

calculate the cumulative surface area for each type of article in the indoor environment. Overall,
confidence in surface area is **robust** for articles like toys because there is a good understanding of the

1340 presence and dimensions in indoor environments.

1340

## 1342 Human Behavior

1343 CEM 3.2 has three different activity patterns: stay-at-home, part-time out-of-the home (daycare, school,

1344 or work), and full-time out-of-the-home. The activity patterns were developed based on the

1345 Consolidated Human Activity Database (CHAD). For all products and articles modeled, the stay-at-1346 home activity pattern was chosen as it is the most protective assumption.

1347

Mouthing durations are a source of uncertainty in human behavior. The data used in this assessment are 1348 1349 based on a study in which parents observed children (n=236) ages 1 month to 5 years of age for 15 1350 minutes per session, for 20 sessions (Smith and Norris, 2003). There was considerable variability in the 1351 data due to behavioral differences among children of the same lifestage. For instance, while children 1352 aged 6-9 months had the highest average mouthing duration for toys at 39 minutes per day, the 1353 minimum duration was 0 minutes, and the maximum was 227 minutes per day. The observers noted that 1354 the items mouthed were made of plastic roughly 50 percent of the mouthing time, but this was not 1355 limited to soft plastic items likely to contain significant plasticizer content. In another study, 169 1356 children aged 3 months to 3 years were monitored by trained observers for 12 sessions at 12 minutes 1357 each (Greene, 2002). They reported mean mouthing durations ranging from 0.8 to 1.3 minutes per day 1358 for soft plastic toys and 3.8 to 4.4 minutes per day for other soft plastic objects (except pacifiers). Thus, 1359 it is likely that the mouthing durations used in this assessment provide a health protective estimate for

- 1360 mouthing of soft plastic items likely to contain DCHP.
- 1361

## 1362 Modeling Tool

1363 Confidence in the model used considers whether the model has been peer review, as well as whether it is

being applied in a manner appropriate to its design and objective. The model used, CEM 3.2, has been

peer review (ERG, 2016), is publicly available, and has been applied in the manner intended by

estimating exposures associated with uses of household products and/or articles. This also considers the

- default values data source(s) such as building and room volumes, interzonal ventilation rates, and air
- exchange rates. Overall confidence in the proper use of CEM for consumer exposure modeling is
- 1369 **robust**.

1370

## 1371 Dermal Modeling for DCHP

Experimental dermal data was identified via the systematic review process to characterize consumer
dermal exposures to liquids or mixtures and formulations containing DCHP, see Section 2.3.1. EPA has
moderate understanding of the scientific evidence and the uncertainties. The determination of
uncertainties supporting scientific evidence is reasonably adequate to characterize exposure estimates,
although the approaches likely overestimate dermal exposures. EPA has a slight confidence in the
dermal exposure to liquid and solid products or articles modeling approach.

1378

1379 A source of uncertainty regarding the dermal absorption of DCHP from products or formulations stems 1380 from the varying concentrations and co-formulants that exist in products or formulations containing 1381 DCHP. For purposes of this risk evaluation, EPA assumes that the absorptive flux of DCHP serves as an 1382 upper bound of potential absorptive flux of chemical into and through the skin for dermal contact with 1383 all liquid products or formulations, and that the modeled absorptive flux of aqueous DCHP serves as an 1384 upper bound of potential absorptive flux of chemical into and through the skin for dermal contact with 1385 all solid products. However, dermal contact with products or formulations that have lower 1386 concentrations of DCHP may exhibit lower rates of flux since there is less material available for absorption. Conversely, co-formulants or materials within the products or formulations may lead to 1387 1388 enhanced dermal absorption, even at lower concentrations. Therefore, it is uncertain whether the products or formulations containing DCHP would result in decreased or increased dermal absorption. 1389 1390 Based on the available dermal absorption data for DCHP. EPA has made assumptions that result in 1391 exposure assessments that are the most human health protective in nature.

1392

1393 Lastly, EPA notes that there is uncertainty with respect to the modeling of dermal absorption of DCHP 1394 from solid matrices or articles and liquid products and formulations. Because there were no available 1395 data related to the dermal absorption of DCHP from solid matrices or articles and liquid products, EPA 1396 has assumed that dermal absorption of DCHP from solid objects would be limited by aqueous solubility 1397 of DCHP. Therefore, to determine the maximum steady-state aqueous flux of DCHP, EPA utilized the 1398 Consumer Exposure Model (CEM) (U.S. EPA, 2023) to first estimate the steady-state aqueous 1399 permeability coefficient of DCHP. The estimation of the steady-state aqueous permeability coefficient 1400 within CEM (U.S. EPA, 2023) is based on a quantitative structure-activity relationship (QSAR) model 1401 presented by ten Berge (2009), which considers chemicals with  $log(K_{ow})$  ranging from -3.70 to 5.49 and 1402 molecular weights ranging from 18 to 584.6. The molecular weight of DCHP falls within the range 1403 suggested by ten Berge (2009), as does the log( $K_{ow}$ ) of DCHP. Therefore, there is a low to medium (due 1404 to assumptions used in migration of DCHP from solid to aqueous media) uncertainty regarding the 1405 accuracy of the QSAR model used to predict the steady-state aqueous permeability coefficient for 1406 DCHP.

1407

## 1408 Modeling Parameters for DCHP Chemical Migration

1409 DCHP is considered a data poor chemical with respect to migration of chemical to saliva, meaning 1410 specific empirical information is scarce. Data were lacking for key parameters to describe the dynamic 1411 physical behavior of DCHP that will influence exposure, particularly the chemical migration rate from 1412 articles mouthed. To address this data gap, a scientifically informed approach was adopted, wherein 1413 values from analogous chemicals sharing comparable physical and chemical properties were leveraged 1414 as surrogates. For the mouthing exposure assessment, EPA used DBP as a surrogate. Based on the DBP 1415 available empirical evidence and the relative similarity in physical chemical characteristics, such as the 1416 larger size, higher molecular weight, and lower solubility of DCHP as compared to DBP can be 1417 expected to result in a slower rate of migration through the polymer matrix and less partitioning to saliva

1418 for DCHP, facilitated the estimation of chemical migration rate.

#### 1419

1420 For chemical migration rates to saliva, existing data were highly variable both within and between 1421 studies. This indicates the significant level of uncertainty for the chemical migration rate, as it may also 1422 differ among similar items due to variations in chemical makeup and polymer structure. As such, an effort was made to choose DBP (DCHP selected surrogate) migration rates likely to be representative of 1423 1424 broad classes of items that make up consumer COUs produced with different manufacturing processes 1425 and material formulations. The physical and chemical characteristics of DCHP and DBP known to affect 1426 chemical migration rates are similar, but the larger size, higher molecular weight, and lower solubility of 1427 DCHP as compared to DBP can be expected to result in a slower rate of migration through the polymer 1428 matrix and less partitioning to saliva for DCHP. Thus, using chemical migration rates for DBP to 1429 calculate the DCHP dose received during mouthing will provide a health protective estimate.

1430

## 1431 Table 5-1. Weight of Scientific Evidence Summary Per Consumer COU

1432

Consumer COU Category and Subcategory	Weight of Scientific Evidence	Overall Confidence
Adhesives and sealants	Two different scenarios were assessed under this COU for products with differing use patterns for which each scenario had varying number of identified product examples (in parenthesis): adhesives for small repairs (2) and automotive adhesives (3). The two scenarios and the products within capture the variability in product formulation and are represented in the high, medium, and low intensity use estimates. The overall confidence in this COU inhalation exposure estimate is robust because the CEM default parameters represent actual use patterns and location of use. For dermal exposure EPA used a dermal flux approach, moderate was selected for this approach because the moderate uncertainty in the partitioning from product to skin and subsequent dermal absorption is not well characterized or confirmed with experimental results. However, other parameters like frequency and duration of use, and surface area in contact are well understood and representative, making the overall confidence in a health protective estimate moderate.	Inhalation – Robust Dermal – Moderate
Plasticizer in other articles with routine direct contact during normal use including rubber articles; plastic articles (hard)	One scenario was assessed under this COU. The scenario considered multiple articles and routine dermal contact with similar use patterns. The scenario for small articles of routine dermal contact was assessed for dermal exposures only because inhalation and ingestion would have low exposure potential due to the small surface area of the articles. The articles with routine contact scenario considered multiple input parameters used in the high, medium, and low intensity use scenarios. The overall confidence in this COU for the dermal exposure assessment is moderate. The dermal absorption estimate assumes that dermal absorption of DCHP from solid objects would be limited by the aqueous solubility of DCHP. EPA has slight confidence in the aspects of the exposure estimate for solid articles because of the high uncertainty in the assumption of partitioning from solid to liquid, and because subsequent dermal absorption is not well characterized. However, other parameters such as frequency and duration of use, and surface area in contact, are well understood and representative, resulting in an overall confidence of moderate in a health protective estimate.	Dermal – Moderate
Other; Other consumer articles that contain dicyclohexyl phthalate	Two different scenarios were assessed under this COU for articles with differing use patterns. The scenarios of outdoor seating (single article in use), and small articles with potential for routine contact (multiple articles) were evaluated. These two scenarios were assessed for dermal exposures. Dermal	Dermal – Moderate

Consumer COU Category and Subcategory	Weight of Scientific Evidence	Overall Confidence
from: inks, toner and colorants; paints and coatings; adhesives and sealants ( <i>e.g.</i> , paper products, textiles, products using cellulose film, etc.)	absorption estimates assumed that dermal absorption of DCHP from solid objects would be limited by the aqueous solubility of DCHP. EPA has slight confidence in the aspects of the exposure estimate for solid articles because of the high uncertainty in the assumption of partitioning from solid to liquid, and because subsequent dermal absorption is not well characterized. However, other parameters such as frequency and duration of use, and surface area in contact, are well understood and representative, resulting in an overall confidence of moderate in a health protective estimate.	

# 1433 **5.2 Indoor Dust Monitoring Weight of Scientific Evidence**

The weight of scientific evidence (WOSE) for the indoor dust exposure assessment of DCHP (Table 1434 1435 5-2) is dependent on studies that include indoor residential dust monitoring data (Table 4-1). Only 1436 studies that included indoor dust samples taken from residences were included for data extraction. In the case of DCHP, three studies were identified as containing data on indoor environments in the United 1437 1438 States and were selected for use in the indoor dust monitoring assessment as described in Section 4.1, Rudel et al. (2001), Guo and Kannan (2011), and Dodson et al. (2015). The Rudel et al. (2001) and Guo 1439 and Kannan (2011) studies were rated "High" quality per the exposure systematic review criteria and 1440 Dodson et al. (2015) was rated "Medium" quality per the exposure systematic review criteria. The 1441 1442 systematic review ratings for the studies are high and medium indicating good reporting and description 1443 of the monitoring from the authors. However, the use of these studies' data in this risk assessment to 1444 represent the U.S. population is a factor considered in the designation of overall confidence in Table 5-2. The low number of samples within each study, and few localities, are used to assign a slight confidence 1445 1446 in the overall use of these data for risk estimates or representative of the U.S. population.

1447

### 1448 Table 5-2. Weight of Scientific Evidence Conclusions for Indoor Dust Ingestion Exposure

		Confidence in	n Model Inputs	Weight of Scientific Evidence Conclusion	
Scenario	Confidence in Data Used ^a	Body Weight ^b	Dust Ingestion Rate ^c		
Indoor exposure to residential dust via ingestionSlight		Robust Moderate		Slight	
^a <u>Rudel et al. (2001)</u> , ^b <u>U.S. EPA (2011b)</u> ^c <u>Özkaynak et al. (202</u>		)11), <u>Dodson et al</u>	<u>I. (2015)</u>		

1449

Table 5-2 presents the level of confidence in the data quality of the input data sets for estimating dust ingestion from monitoring data, including the DCHP dust monitoring data (Confidence in Data Used column in Table 5-2), the estimates of U.S. body weights, and the estimates of dust ingestion rates, according to the following rubric:

1454

- Robust confidence means the supporting weight of scientific evidence outweighs the
   uncertainties to the point that the assessor has decided that it is unlikely that the uncertainties
   could have a significant effect on the exposure estimate.
- Moderate confidence means the supporting scientific evidence weighed against the uncertainties

- is reasonably adequate to characterize exposure estimates, but uncertainties could have an effecton the exposure estimate.
- Slight confidence means the assessor is making the best scientific assessment possible in the absence of complete information. There may be significant uncertainty in the underlying data that needs to be considered.
- 1464
- 1465 These confidence conclusions were derived from a combination of systematic review (*i.e.*, the quality 1466 determinations for individual studies) and the assessor's professional judgment (see Table 5-2).
- 1467

1468 Monitoring data collected in the United States were identified for DCHP in Rudel et al. (2001), Guo and 1469 Kannan (2011), and Dodson et al. (2015). In Rudel et al. (2001), six indoor dust samples were collected from multiple surfaces in offices and various home environments (attic, living room, and basement). In 1470 Guo and Kannan (2011) 33 carpet flooring dust samples were collected in several homes between 2007 1471 1472 and 2008 in New York. Lastly in Dodson et al. (2015), 49 dust samples were collected from multiple 1473 surfaces in homes in California in 2006. Although the studies have differing numbers of samples, 1474 sampling surfaces, indoor environments, and locations, the low number of studies, sampling locations, 1475 and samples do not capture a representative indoor dust U.S. distribution. EPA assigned slight 1476 confidence to the use of these studies reporting dust concentrations.

1477

Body weight data was obtained from the *Exposure Factors Handbook* (U.S. EPA, 2011b). This source is considered the default for exposure related inputs for EPA risk assessments and is typically used unless there is a particular reason to seek alternative data. Because the Handbook is generally considered the gold standard input for body weight, and because the underlying body weight data were derived from the U.S. nationally representative NHANES data set, EPA has assigned robust confidence to the use of this model input.

1484

1485 Total daily dust intake was obtained from <u>Özkaynak et al. (2022)</u>. This study used a mechanistic 1486 modeling approach to aggregate data from a wide variety of input variables (Table 5-3). These input 1487 variables were derived from several scientific sources as well as from the professional judgment of the 1488 study authors. The dust ingestion rates are similar to those found in the Exposure Factors Handbook for 1489 children less than 1 year old but diverge above this age (U.S. EPA, 2011a) (Table 5-4). The Özkaynak et 1490 al. (2022) dust ingestion rates are one-half to approximately one-fifth as large, depending on age. This is 1491 because the Handbook rates are a synthesis of several studies in the scientific literature, including tracer 1492 studies that use elemental residues in the body to estimate the ingestion of soil and dust. According to 1493 the discussion presented in Özkaynak et al. (2022), these tracer studies may be biased high, and in fact 1494 as shown in Figure 4 of Özkaynak et al. (2022), non-tracer studies align much more closely with the dust 1495 ingestion rates used in this analysis. Because some input variables were unavailable in the literature and 1496 had to be based on professional judgment, and the dust ingestion rates differ from those in the 1497 Handbook, EPA has assigned moderate confidence to this model input.

1498

## 5.2.1 Assumptions in Estimating Intakes from Indoor Dust Monitoring

1499

## 5.2.1.1 Assumptions for Monitored DCHP Concentrations in Indoor Dust

1500 The DCHP concentrations in indoor dust were derived from <u>Rudel et al. (2001)</u>, <u>Guo and Kannan</u> 1501 (2011), and <u>Dodson et al. (2015)</u>. The studies identified the sampling locations and rooms as typical

1501 indoor locations. A key assumption made in this analysis is that dust concentrations in living rooms,

1503 attics, basements, and offices are representative of those in the remainder of the home. Another

important assumption is that a very small number of samples and localities within the studies' data is

assumed to represent the U.S. population.

## 1506 5.2.1.2 Assumptions for Body Weights

Body weights were taken from the *Exposure Factors Handbook* (U.S. EPA, 2011b), in which they were derived from the NHANES 1999 to 2006 data set. The NHANES studies were designed to obtain a nationally representative data set for the United States and include weight adjustment for oversampling of certain groups (children, adolescents 12 to 19 years, persons 60+ years of age, low-income persons, African Americana and Maxican Americana). Bady weights were appreciated into the one persons,

- 1511 African Americans, and Mexican Americans). Body weights were aggregated into the age ranges shown 1512 in Table 4-2 and Table 4-3 and were averaged by sex
- 1512 in Table 4-2 and Table 4-3 and were averaged by sex.

## 5.2.1.3 Assumptions for Dust Ingestion Rates

To estimate daily intake of DCHP in residential indoor dust, a daily rate of dust ingestion is required.
EPA used rates from <u>Özkaynak et al. (2022)</u> that modeled to estimate dust and soil intakes for children
from birth to 21 years of age. A probabilistic approach was used in that study to assign exposure
parameters including behavioral and biological variables. The exposure parameters are summarized in
Table 5-3 and the statistical distributions chosen are reproduced in detail in the supplemental material
for <u>Özkaynak et al. (2022)</u>.

1520

1513

## 1521 Table 5-3. Summary of Variables from Özkaynak et al. 2022 Dust/Soil Intake Model

Variable	Description	Units	Source
Bath_days_max	Maximum # days between baths/showers	days	Ozkaynak et al. (2011), based on Kissel 2003 (personal communication)
Dust_home_hard	Dust loading on hard floors	$\mu g/cm^2$	Adgate et al. (1995)
Dust_home_soft	Dust loading on carpet	$\mu g/cm^2$	Adgate et al. (1995)
F_remove_bath	Fraction of loading removed by bath or shower	(-)	Professional judgment
F_remove_hand_mouth	Fraction of hand loading removed by one mouthing event	(-)	<u>Kissel et al. (1998)</u> and <u>Hubal et</u> <u>al. (2008)</u>
F_remove_hand_wash	Fraction of hand loading removed by hand washing	(-)	Professional judgment
F_remove_hour	Fraction of dermal loading removed by passage of time	(-)	Ozkaynak et al. (2011)
F_transfer_dust_hands	Fraction of floor dust loading transferred to hands by contact	(-)	Ozkaynak et al. (2011)
F_transfer_object_mouth	Fraction transferred from hands to mouth	(-)	Zartarian et al. (2005), based on Leckie et al. (2000)
Hand_contact_ratio	Ratio of floor area contacted hourly to the hand surface area	1/hour	Freeman et al. (2001)and Zartarian et al. (1997)
Hand_load_max	Maximum combined soil and dust loading on hands	$\mu g/cm^2$	Ozkaynak et al. (2011)
Hand_washes_per_day	Number of times per day the hands are washed	1/day	Zartarian et al. (2005)
Object_floor_dust_ratio	Relative loadings of object and floor dust after contact	(-)	Professional judgment, based on Gurunathan et al. (1998)
P_home_hard	Probability of being in part of home with hard floor	(-)	Ozkaynak et al. (2011)
P_home_soft	Probability of being in part of home with carpet	(-)	Ozkaynak et al. (2011)

Variable	Description	Units	Source
Adherence_soil ^a	Accumulated mass of soil that is transferred onto skin	mg/cm ²	Zartarian et al. (2005), based on Holmes et al. (1999), Kissel et al. (1996a), and Kissel et al. (1996b)
Hand_mouth_fraction ^a	Fraction of hand area of one hand contacting the inside of the mouth	(-)	<u>Tsou et al. (2017)</u>
Hand_mouth_freq ^a (indoor/outdoor)	Frequency of hand-mouth contacts per hour while awake – separate rate for indoor/outdoor behavior	(-)	Black et al. (2005) and Xue et al. (2007)
Object_mouth_area ^a	Area of an object inserted into the mouth	cm ²	Leckie et al. (2000)
Object_mouth_freq ^a	Frequency at which objects are moved into the mouth	(-)	Xue et al. (2010)
P_blanket ^b	Probability of blanket use	(-)	Professional judgment
F_blanket ^b	Protective barrier factor of blanket when used	(-)	Professional judgment
Pacifier_size ^b	Area of pacifier surface	cm ²	Özkaynak et al. (2022)
Pacifier_frac_hard ^b	Fraction of pacifier drops onto hard surface	(-)	Professional judgment
Pacifier_frac_soft ^b	Fraction of pacifier drops onto soft surface	(-)	Professional judgment
Pacifier_transfer ^b	Fraction of dust transferred from floor to pacifier	()	Extrapolated from <u>Rodes et al.</u> (2001), <u>Beamer et al.</u> (2009), and <u>Hubal et al.</u> (2008)
Pacifier_washing ^b	Composite of the probability of cleaning the pacifier after it falls and efficiency of cleaning	()	Conservative assumption (zero cleaning is assumed)
Pacifier_drop ^b	Frequency of pacifier dropping	(-)	<u>Tsou et al. (2015)</u>
P_pacifier ^b	Probability of pacifier use	(-)	<u>Tsou et al. (2015)</u>
^{<i>a</i>} Variable distributions dif ^{<i>b</i>} Variable only applies to a		1	1

1522

### 5.2.1 Uncertainties in Estimating Intakes from Monitoring Data

1523

## 5.2.1.1 Uncertainties for Monitored DCHP Concentrations in Indoor Dust

1524 Indoor dust concentrations were derived from Rudel et al. (2001), Guo and Kannan (2011), and Dodson et al. (2015), which sampled residential house dust in New York and California. Uncertainties arise from 1525 the low number of samples and localities within the monitoring studies used to represent the U.S. 1526 population. It is possible that sampling biases were introduced by the choice of study location, by the 1527 1528 choice to include only households that contain children, and by differences among the households that chose to participate in the study. Differences in consumer behaviors, housing type and quality, tidiness, 1529 1530 and other variables that affect DCHP concentrations in household dust are possible between 1531 participating households and the general population.

## 1532 5.2.1.2 Uncertainties for Body Weights

1533 Body weights were obtained from *Exposure Factors Handbook* (U.S. EPA, 2011b), which contains data

1534 from the 1999 to 2006 NHANES. Body weights were aggregated across lifestages and averaged by sex.

1535 In general, body weights have increased in the United States since 2006 (CDC, 2013), which may lead

to an underestimate of body weight in this analysis. This would lead to an overestimate of DCHP dose

per unit body weight, because actual body weights in the U.S. population may be larger than those
 assumed in this analysis.

## 1539

## 5.2.1.3 Uncertainties for Dust Ingestion Rates

1540 Dust ingestion rates were obtained from <u>Özkaynak et al. (2022)</u>, which uses mechanistic methods (the

1541 SHEDS model) to estimate dust ingestion using a range of parameters (Table 5-3). Each of these

1542 parameters is subject to uncertainty—especially those that are derived primarily from the professional

judgment of the authors. Because of the wide range of parameters and the lack of comparator data

against which to judge, EPA is unable to determine the direction of potential bias in each of the

parameters individually. For dust ingestion rates overall, the rates derived from <u>Özkaynak et al. (2022)</u> can be compared to those found in the *Exposure Factors Handbook* (U.S. EPA, 2017) (Table 5-4).

1547

1548	Table 5-4. Comparison between Özkaynak et al. 2022 and <i>Exposure Factors Handbook</i> Dust
1549	Ingestion Rates

Age 1	Range	0-	1-	3–	6 m-	1-	2-	3-	6-	11-	16-
0	0	<1 m	<3 m	<6 m	<1 y	<2 y	<3 y	<6 y	<11 y	<16 y	<21 y
Central	Özkaynak et	19	21	23	26	23	14	15	13	8.8	3.5
tendency	<u>al. (2022)</u>										
dust	U.S. EPA	20	20	20	20	50	30	30	30	20 ^a	20
ingestion	(2017)										
(mg/day)											

m = month(s); y = year(s)

^{*a*} The intake for an 11-year old based on the *Exposure Factors Handbook* is 30 mg/day. The age ranges do not align between the two sources in this instance.

1550

1551 The <u>Özkaynak et al. (2022)</u> dust intake estimates for children above 1 year old are substantially lower

than those in the *Exposure Factors Handbook* (U.S. EPA, 2011b), while the estimate for children

between 1 month and 1 year old are slightly higher. The authors of the <u>Özkaynak et al. (2022)</u> study

1554 offer some justification for the discrepancy by noting that the Handbook recommendations are a

synthesis of several types of study, including tracer studies that "[suffer] from various sources of

uncertainty that could lead to considerable study-to-study variations." Biokinetic and activity pattern
studies, such as Von Lindern et al. (2016) and Wilson et al. (2013) respectively, achieve results that are

1558 closer to the <u>Özkaynak et al. (2022)</u> results (see Fig. 4, <u>Özkaynak et al. (2022)</u>).

1559

1565

1566

# 5.2.1.4 Uncertainties in Interpretation of Monitored DCHP Dose Estimates

1560There are several potential challenges in interpreting available indoor dust monitoring data. The1561challenges include the following:

- Number of samples and locations used to represent the U.S. population.
- Samples may have been collected at exposure times or for exposure durations not expected to be consistent with a presumed hazard based on a specified exposure time or duration.
  - Samples may have been collected at a time or location when there were multiple sources of DCHP that included non-TSCA COUs.
- None of the identified monitoring data contained source apportionment information that could be used to determine the fraction of DCHP in dust samples that resulted from a particular TSCA or non-TSCA COU. Therefore, these monitoring data represent background concentrations of DCHP and are an estimate of aggregate exposure from all residential sources.

- Activity patterns may differ according to demographic categories (*e.g.*, stay at home/work from home individual vs. an office worker) that can affect exposures especially to articles that continually emit a chemical of interest.
- Some indoor environments may have more ventilation than others, which may change across seasons.

## 1576 **5.3 Indoor Dust Modeling Weight of Scientific Evidence**

- 1577 See Section 5.1 for a detailed description of sources of uncertainties from CEM modeling and
- 1578 reconstruction of indoor dust scenarios from uncertainties to data variability.

# 1579 6 CONCLUSION AND STEPS TOWARDS RISK 1580 CHARACTERIZATION

## 1581 Indoor Dust

For the indoor exposure assessment, EPA considered modeling and monitoring data. Monitoring data is expected to represent aggregate exposure to DCHP in dust resulting from all sources present in a home. Although it is not a good indicator of individual contributions of specific COUs, it provides a real-world indicator of total exposure through dust. However, available DCHP monitoring data had few samples and study locations. Without additional samples it is difficult to determine if the data is representative of the U.S. population. There were no indoor modeling article or product scenarios that could be used to assess indoor DCHP releases and potential exposures.

- 1589
- 1590 Due to the slight confidence evaluation of the monitoring assessment, a risk estimate based on these data 1591 was not derived. Additionally, because the monitoring data was not found to be representative of the
- 1592 U.S. population and was not apportioned to DCHP-containing items, the typical monitoring and
- modeling dose comparison was unlikely to yield useful information.

## 1595 Consumer

- 1596 All COU exposure dose results summarized in Section 3 have a moderate to robust confidence and
- hence can be used for risk estimates calculations and to determine risk to the various lifestages. The
- 1598 consumer assessment has low, medium, and high exposure scenarios which represent use patterns of
- high, medium, and low intensity uses. The high exposure scenarios capture use patterns for high
   exposure potential from high frequency and duration use patterns, extensive mouthing behaviors, and
- 1601 exposure potential from high frequency and duration use patterns, extensive mouthing behaviors, and 1601 conditions that promote greater migration of DCHP from products/articles to sweat and skin. Low and
- 1601 conditions that promote greater migration of DCHP from products/articles to sweat and skin. Low and 1602 medium exposure scenarios represent less intensity in use patterns, mouthing behaviors, and conditions
- 1603 that promote DCHP migration to sweat and skin, capturing populations with different lifestyles.

# 1604 **7 REFERENCES**

Adgate, JL; Weisel, C; Wang, Y; Rhoads, GG; Lioy, PJ. (1995). Lead in house dust: Relationships
between exposure metrics. Environ Res 70: 134-147. <u>http://dx.doi.org/10.1006/enrs.1995.1058</u>
AIA. (2019). Comment submitted by David Hyde, Director, Environmental Policy, Aerospace Industries
Association (AIA). Dicyclohexyl phthalate; TSCA Review: Docket EPA-HQ-OPPT-2018-0504-
0006. August 2, 2019. <u>https://www.regulations.gov/document?D=EPA-HQ-OPPT-2018-0504-</u>
0006 Reamon B: Canalas RA: Laskia IO (2000) Developing probability distributions for transfer
Beamer, P; Canales, RA; Leckie, JO. (2009). Developing probability distributions for transfer
efficiencies for dermal exposure [Review]. J Expo Sci Environ Epidemiol 19: 274-283. http://dx.doi.org/10.1038/jes.2008.16
Black, K; Shalat, SL; Freeman, NCG; Jimenez, M; Donnelly, KC; Calvin, JA. (2005). Children's mouthing and food-handling behavior in an agricultural community on the US/Mexico border. J
Expo Anal Environ Epidemiol 15: 244-251. <u>http://dx.doi.org/10.1038/sj.jea.7500398</u>
CDC. (2013). National Health and Nutrition Examination Survey Data (NHANES) [Database].
<u>CDC.</u> (2013). Child development: Positive parenting tips. Available online at
<u>https://www.cdc.gov/ncbddd/childdevelopment/positiveparenting/index.html</u> (accessed April 3,
2024).
<u>CETCO.</u> (2018). Technical Data Sheet (TDS): Cetguard Catalyst Powder. Hoffman Estates, IL.
https://www.mineralstech.com/docs/default-source/performance-materials-
documents/cetco/building-materials/technical-data-
sheets/tds_cetguard_catalyst_powder_am_en_201803_v2.pdf
<u>CPSC.</u> (2015). Exposure assessment: Composition, production, and use of phthalates. Cincinnati, OH:
Prepared by: Toxicology Excellence for Risk Assessment Center at the University of Cincinnati.
https://web.archive.org/web/20190320060357/https://www.cpsc.gov/s3fs-
public/pdfs/TERAReportPhthalates.pdf
Danish EPA. (2010). Phthalates in plastic sandals. https://www2.mst.dk/udgiv/publications/2010/978-
87-92708-67-0/pdf/978-87-92708-66-3.pdf
DeWALT. (2020). Safety Data Sheet (SDS): Hammer capsule. Toewson, MD.
DeWALT. (2024). DeWALT Hammer Capsule, Tanner bolt: Online listing. Toewson, MD.
https://www.tannerbolt.com/pow-06704-5-8-powers-hammer-capsule-drive-in-type-capsule-
adhesives
Dodson, RE; Camann, DE; Morello-Frosch, R; Brody, JG; Rudel, RA. (2015). Semivolatile organic
compounds in homes: strategies for efficient and systematic exposure measurement based on
empirical and theoretical factors. Environ Sci Technol 49: 113-122.
http://dx.doi.org/10.1021/es502988r
DTL (2016). Survey No. 117: Determination of migration rates for certain phthalates. Copenhagen,
Denmark: Danish Environmental Protection Agency.
https://www2.mst.dk/Udgiv/publications/2016/08/978-87-93529-01-4.pdf
Earthjustice. (2019). Comment submitted by Eve C. Gartner, Staff Attorney, Earthjustice: 84-61-7
DCHP Technical Report Final 11-20. Dicyclohexyl phthalate; TSCA Review: Docket EPA-HQ-
OPPT-2018-0504-0011. December 3, 2019. https://www.regulations.gov/document?D=EPA-
<u>HQ-OPPT-2018-0504-0011</u>
ERG. (2016). Peer review of EPA's Consumer Exposure Model and draft user guide (final peer review
report). Washington, DC: U.S. Environmental Protection Agency.
Ford Motor Company. (2015). SDS - metal bonding adhesive.
Freeman, NCG; Jimenez, M; Reed, KJ; Gurunathan, S; Edwards, RD; Roy, A; Adgate, JL; Pellizzari,
ED; Quackenboss, J; Sexton, K; Lioy, PJ. (2001). Quantitative analysis of children's
microactivity patterns: The Minnesota Children's Pesticide Exposure Study. J Expo Anal
Environ Epidemiol 11: 501-509. http://dx.doi.org/10.1038/sj.jea.7500193

1653	Gans Ink and Supply. (2018). X102452, X102822, X102839, X102840, L-3049. Gans Ink and Supply.
1654	https://www.gansink.com/wp-content/uploads/2018/11/SDS-642-SDS-Version-11-9-18.pdf
1655	Greene, MA. (2002). Mouthing times among young children from observational data. Bethesda, MD:
1656	U.S. Consumer Product Safety Commission.
1657	Guo, Y; Kannan, K. (2011). Comparative assessment of human exposure to phthalate esters from house
1658	dust in China and the United States. Environ Sci Technol 45: 3788-3794.
1659	http://dx.doi.org/10.1021/es2002106
1660	Gurunathan, S; Robson, M; Freeman, N; Buckley, B; Roy, A; Meyer, R; Bukowski, J; Lioy, PJ. (1998).
1661 1662	Accumulation of chlorpyrifos on residential surfaces and toys accessible to children. Environ Health Perspect 106: 9-16. <u>http://dx.doi.org/10.2307/3433627</u>
1663	Hallstar. (2022). Safety Data Sheet (SDS): UNIPLEX TM 250. Chigaco, IL.
1664	https://www.hallstarindustrial.com/product/uniplex-250/
1665	Henkel Corporation. (2019). Loctite Ablestik 2035SC Safety Data Sheet. Henkel Corporation.
1666	https://www.henkel-adhesives.com/us/en/product/die-attach-
1667	adhesives/loctite_ablestik2035sc.html
1668	Holmes, KK, Jr; Shirai, JH; Richter, KY; Kissel, JC. (1999). Field measurement of dermal soil loadings
1669	in occupational and recreational activities. Environ Res 80: 148-157.
1670	http://dx.doi.org/10.1006/enrs.1998.3891
1671	Hubal, EA; Nishioka, MG; Ivancic, WA; Morara, M; Egeghy, PP. (2008). Comparing surface residue
1672	transfer efficiencies to hands using polar and nonpolar fluorescent tracers. Environ Sci Technol
1673	42: 934-939. http://dx.doi.org/10.1021/es071668h
1674	HYDRO-GARD. (2017a). Safety Data Sheet (SDS): Gard-Deck® Hardener (BPO). Yorba Linda, CA.
1675	HYDRO-GARD. (2017b). Technical Data Sheet (TDS): Gard-Deck® Hardener (BPO). Yorba Linda,
1676	CA.
1677	HYDRO-GARD. (2024). HYDRO-GARD Gard-Deck System. Available online at https://www.hydro-
1678	gard.com/index.php/gard-deck/ (accessed September 30, 2024).
1679	Hydro-Gard LLC. (2017). Gard-Deck ® hardener 500. Hydro-Gard LLC. http://hydro-
1680	gard.com/uploads/Gard%20Deck%20Hardener%20500%20SDS%20Sheet%20with%20footer.p
1681	$\underline{df}$
1682	ITW Permatex. (2018). Duco cement safety data sheet. ITW Permatex.
1683	https://441py33rout1ptjxn2lupv31-wpengine.netdna-ssl.com/wp-
1684	content/uploads/tech_docs/sds/03_Canada-English/62435_03.pdf
1685	Kissel, JC. (2011). The mismeasure of dermal absorption. J Expo Sci Environ Epidemiol 21: 302-309.
1686	http://dx.doi.org/10.1038/jes.2010.22
1687	Kissel, JC; Richter, KY; Fenske, RA. (1996a). Factors affecting soil adherence to skin in hand-press
1688	trials. Bull Environ Contam Toxicol 56: 722-728. <u>http://dx.doi.org/10.1007/s001289900106</u>
1689	Kissel, JC; Richter, KY; Fenske, RA. (1996b). Field measurement of dermal soil loading attributable to
1690	various activities: Implications for exposure assessment. Risk Anal 16: 115-125.
1691	http://dx.doi.org/10.1111/j.1539-6924.1996.tb01441.x
1692	Kissel, JC; Shirai, JH; Richter, KY; Fenske, RA. (1998). Investigation of dermal contact with soil in
1693	controlled trials. Journal of Soil Contamination 7: 737-752.
1694	http://dx.doi.org/10.1080/10588339891334573
1695	LANXESS. (2021). 2021 LANXESS Product Information Spreadsheet. Cologne: LANXESS Solutions
1696	US Inc.
1697	Leckie, JO; Naylor, KA; Canales, RA; Ferguson, AC; Cabrera, NL; Hurtado, AL; Lee, K; Lin, AY;
1698	Ramirez, JD; VM, V. (2000). Quantifying children's microlevel activity data from existing
1699	videotapes. (Reference No. U2F112OT-RT. 2000). Washington, DC: U.S. Environmental
1700	Protection Agency.

1701	LORD Corporation. (2017). Safety Data Sheet (SDS): Fusor 108B, 109B Metal Bonding ADH PT B.
1702	Cary, NC. https://www.parker.com/content/dam/Parker-com/Literature/AssemblyProtection-
1703	Solutions-Division/Safety-Datasheets/SDS-MSDS-Safety-Data-SheetFUSOR-108B109B-
1704	METAL-BONDING-ADH-PT-B.pdf
1705	Lord Corporation. (2024). Lord Fusor Metal Adhesive Medium 7.6 OZ. Available online at
1706	https://www.amazon.com/Lord-Fusor-ADHESIVE-MEDIUM-FUS-108B/dp/B002CMR8WM
1707	(accessed September 26, 2024).
1708	MEMA. (2019). Comment submitted by Catherine M. Wilmarth, Attorney, Alliance of Automobile
1709	Manufacturers and Laurie Holmes, Senior Director, Environmental Policy, Motor & Equipment
1710	Manufacturers Association (MEMA). (EPA-HQ-OPPT-2019-0131-0022). Alliance of
1711	Automobile Manufacturers and Motor & Equipment Manufacturers Association.
1712	https://www.regulations.gov/document?D=EPA-HQ-OPPT-2019-0131-0022
1713	Midwest Technology Products. (2024). Midwest Technology Products: Permatex Duco Cement.
1714	Available online at https://www.midwesttechnology.com/duco-cement/ (accessed October 9,
1715	2024).
1716	MKT. (2018). Safety Data Sheet (SDS): Liquid Roc 300 Twin Tube. Lonoke, AR.
1717	https://www.mktfastening.com/sites/default/files/content/downloadable-
1718	<u>files/lr300_twin_tube_sds_0.pdf</u>
1719	MKT. (2024). Amazon listing: MKT Polyester Liquid ROC 300 Chemical Anchor, 5.5 oz Pouch.
1720	Available online at <a href="https://www.amazon.com/MKT-Polyester-Liquid-Chemical-">https://www.amazon.com/MKT-Polyester-Liquid-Chemical-</a>
1721	Anchor/dp/B00D8JEHMW (accessed September 26, 2024).
1722	Niino, T; Asakura, T; Ishibashi, T; Itoh, T; Sakai, S; Ishiwata, H; Yamada, T; Onodera, S. (2003). A
1723	simple and reproducible testing method for dialkyl phthalate migration from polyvinyl chloride
1724	products into saliva simulant. Shokuhin Eiseigaku Zasshi 44: 13-18.
1725	http://dx.doi.org/10.3358/shokueishi.44.13
1726	Niino, T; Ishibashi, T; Itho, T; Sakai, S; Ishiwata, H; Yamada, T; Onodera, S. (2001). Monoester
1727	formation by hydrolysis of dialkyl phthalate migrating from polyvinyl chloride products in
1728	human saliva. J Health Sci 47: 318. <u>http://dx.doi.org/10.1248/jhs.47.318</u>
1729	OECD. (2004). Test No. 428: Skin absorption: In vitro method. Paris, France.
1730	http://dx.doi.org/10.1787/9789264071087-en
1731	Özkaynak, H; Glen, G; Cohen, J; Hubbard, H; Thomas, K; Phillips, L; Tulve, N. (2022). Model based
1732 1733	prediction of age-specific soil and dust ingestion rates for children. J Expo Sci Environ
1733	Epidemiol 32: 472-480. <u>http://dx.doi.org/10.1038/s41370-021-00406-5</u> Ozkaynak, H; Xue, J; Zartarian, VG; Glen, G; Smith, L. (2011). Modeled estimates of soil and dust
1734	ingestion rates for children. Risk Anal 31: 592-608. http://dx.doi.org/10.1111/j.1539-
1736	<u>6924.2010.01524.x</u>
1737	Parchem. (2024). Parchem: Dicyclohexyl phthalate. Available online at
1738	https://www.parchem.com/chemical-supplier-distributor/dicyclohexyl-phthalate-038878
1739	(accessed November 5, 2024).
1740	Permatex. (2021). Safety Data Sheet (SDS): Duco cement. Solon, OH.
1741	https://archpdfs.lps.org/Chemicals/Duco_Cement.pdf
1742	Permatex. (2024). Amazon listing: Duco Cement Multi-Purpose Household Glue - 1 fl oz. Available
1743	online at https://www.amazon.com/Duco-Cement-Multi-Purpose-Household-
1744	Glue/dp/B0000A605H/ref=sr_1_1?crid=UO0IFPFGUTEE&dib=eyJ2IjoiMSJ9. KzpHc3863oh7
1745	YHdqKmXtdl4zuHqoyUYEVGEWizlHkvGjHj071QN20LucGBJIEps.sBJgmuEJPN8RvG711Z
1746	DI6kdz3ZgbgQxuIbuajEVYWHc&dib_tag=se&keywords=duco+cement&gid=1727379759&s=
1747	hpc&sprefix=duco+cement%2Chpc%2C51&sr=1-1 (accessed October 9, 2024).

1748 Rodes, CE; Newsome, JR; Vanderpool, RW; Antley, JT; Lewis, RG. (2001). Experimental methodologies and preliminary transfer factor data for estimation of dermal exposures to 1749 particles. J Expo Anal Environ Epidemiol 11: 123-139. http://dx.doi.org/10.1038/sj.jea.7500150 1750 Rudel, RA; Brody, JG; Spengler, JD; Vallarino, J; Geno, PW; Sun, G; Yau, A. (2001). Identification of 1751 selected hormonally active agents and animal mammary carcinogens in commercial and 1752 1753 residential air and dust samples. J Air Waste Manag Assoc 51: 499-513. 1754 http://dx.doi.org/10.1080/10473289.2001.10464292 1755 Smith, SA; Norris, B. (2003). Reducing the risk of choking hazards: Mouthing behaviour of children 1756 aged 1 month to 5 years. Ini Contr Saf Promot 10: 145-154. 1757 http://dx.doi.org/10.1076/icsp.10.3.145.14562 ten Berge, W. (2009). A simple dermal absorption model: Derivation and application. Chemosphere 75: 1758 1759 1440-1445. http://dx.doi.org/10.1016/j.chemosphere.2009.02.043 Tsou, MC; Özkaynak, H; Beamer, P; Dang, W; Hsi, HC; Jiang, CB; Chien, LC. (2015). Mouthing 1760 1761 activity data for children aged 7 to 35 months in Taiwan. J Expo Sci Environ Epidemiol 25: 388-1762 398. http://dx.doi.org/10.1038/jes.2014.50 Tsou, MC; Özkaynak, H; Beamer, P; Dang, W; Hsi, HC; Jiang, CB; Chien, LC. (2017). Mouthing 1763 1764 activity data for children age 3 to <6 years old and fraction of hand area mouthed for children age <6 years old in Taiwan. J Expo Sci Environ Epidemiol 28: 182-192. 1765 http://dx.doi.org/10.1038/jes.2016.87 1766 U.S. EPA. (2004). Risk Assessment Guidance for Superfund (RAGS), volume I: Human health 1767 1768 evaluation manual. (part E: Supplemental guidance for dermal risk assessment). 1769 (EPA/540/R/99/005). Washington, DC: U.S. Environmental Protection Agency, Risk 1770 Assessment Forum. https://www.epa.gov/risk/risk-assessment-guidance-superfund-rags-part-e 1771 U.S. EPA. (2006). A framework for assessing health risk of environmental exposures to children. (EPA/600/R-05/093F). Washington, DC: U.S. Environmental Protection Agency, Office of 1772 1773 Research and Development, National Center for Environmental Assessment. 1774 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158363 U.S. EPA. (2011a). Exposure Factors Handbook, Chapter 6: Inhalation rates. Washington, DC. 1775 1776 https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6 1777 U.S. EPA. (2011b). Exposure Factors Handbook, Chapter 8: Body weight studies. Washington, DC. 1778 https://www.epa.gov/expobox/exposure-factors-handbook-chapter-8 1779 U.S. EPA. (2011c). Exposure factors handbook: 2011 edition [EPA Report]. (EPA/600/R-090/052F). 1780 Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development, 1781 National Center for Environmental Assessment. 1782 https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100F2OS.txt 1783 U.S. EPA. (2017). Update for Chapter 5 of the Exposure Factors Handbook: Soil and dust ingestion 1784 [EPA Report]. (EPA/600R-17/384F). Washington, DC: National Center for Environmental 1785 Assessment, Office of Research and Development. 1786 https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100TTX4.txt 1787 U.S. EPA. (2019a). Chemical data reporting (2012 and 2016 public CDR database). Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics. Retrieved 1788 1789 from https://www.epa.gov/chemical-data-reporting 1790 U.S. EPA. (2019b). Meeting with Vertellus and EPA to discuss conditions of use for dicyclohexyl 1791 phthalate. Washington, DC. https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0504-1792 0021 1793 U.S. EPA. (2020a). 2020 CDR data [Database]. Washington, DC: U.S. Environmental Protection 1794 Agency, Office of Pollution Prevention and Toxics. Retrieved from 1795 https://www.epa.gov/chemical-data-reporting/access-cdr-data

1796	U.S. EPA. (2020b). Meeting with EPA and Futamura USA to discuss conditions of use for dicyclohexyl
1797	phthalate. Washington, DC. https://www.regulations.gov/comment/EPA-HQ-OPPT-2018-0504-
1798	0045
1799	U.S. EPA. (2023). Consumer Exposure Model (CEM) Version 3.2 User's Guide. Washington, DC.
1800 1801	https://www.epa.gov/tsca-screening-tools/consumer-exposure-model-cem-version-32-users- guide
1802	U.S. EPA. (2024a). Consumer Exposure Analysis for Diisononyl Phthalate (DINP). Washington, DC:
1803	Office of Pollution Prevention and Toxics. <u>https://www.regulations.gov/docket/EPA-HQ-OPPT-</u>
1804	2018-0436
1805	U.S. EPA. (2024b). Draft Consumer Exposure Analysis for Dicyclohexyl Phthalate (DCHP).
1806	Washington, DC: Office of Pollution Prevention and Toxics.
1807	U.S. EPA. (2024c). Draft Consumer Risk Calculator for Dicyclohexyl Phthalate (DCHP). Washington,
1808	DC: Office of Pollution Prevention and Toxics.
1809	U.S. EPA. (2024d). Draft Environmental Media and General Population and Environmental Exposure
1810	Assessment for Dicyclohexyl Phthalate (DCHP). Washington, DC: Office of Pollution
1811	Prevention and Toxics.
1812	U.S. EPA. (2024e). Draft physical chemistry and fate and transport assessment for dicyclohexyl
1813	phthalate (DCHP). Washington, DC: Office of Pollution Prevention and Toxics.
1814	U.S. EPA. (2024f). Draft Risk Evaluation for Dicyclohexyl Phthalate (DCHP). Washington, DC: Office
1815	of Pollution Prevention and Toxics.
1816	von Lindern, I; Spalinger, S; Stifelman, ML; Stanek, LW; Bartrem, C. (2016). Estimating children's
1817	soil/dust ingestion rates through retrospective analyses of blood lead biomonitoring from the
1818	Bunker Hill Superfund Site in Idaho. Environ Health Perspect 124: 1462-1470.
1819	http://dx.doi.org/10.1289/ehp.1510144
1820	WEICON GmbH & Co. KG. (2018). RK-1300 - RK-1500 Activator. WEICON GmbH & Co. KG.
1821	https://www.weicon.de/media/pdf/0b/2b/43/MSDS_105622_EN_EN_RK-1300-RK-1500-
1822	<u>Activator.pdf</u>
1823	Wilson, R; Jones-Otazo, H; Petrovic, S; Mitchell, I; Bonvalot, Y; Williams, D; Richardson, GM. (2013).
1824	Revisiting dust and soil ingestion rates based on hand-to-mouth transfer. Hum Ecol Risk Assess
1825	19: 158-188. <u>http://dx.doi.org/10.1080/10807039.2012.685807</u>
1826	WSDE. (2020). High Priority Chemicals Data System (HPCDS) [Database].
1827	https://hpcds.theic2.org/Search
1828	Xue, J; Zartarian, V; Moya, J; Freeman, N; Beamer, P; Black, K; Tulve, N; Shalat, S. (2007). A meta-
1829	analysis of children's hand-to-mouth frequency data for estimating nondietary ingestion
1830	exposure. Risk Anal 27: 411-420. http://dx.doi.org/10.1111/j.1539-6924.2007.00893.x
1831	Xue, J; Zartarian, V; Tulve, N; Moya, J; Freeman, N; Auyeung, W; Beamer, P. (2010). A meta-analysis
1832	of children's object-to-mouth frequency data for estimating non-dietary ingestion exposure. J
1833	Expo Sci Environ Epidemiol 20: 536-545. <u>http://dx.doi.org/10.1038/jes.2009.42</u>
1834	Zartarian, VG; Ferguson, AC; Leckie, JO. (1997). Quantified dermal activity data from a four-child pilot
1835	field study. J Expo Anal Environ Epidemiol 7: 543-552.
1836	Zartarian, VG; Xue, J; Ozkaynak, H; Dang, W; Glen, G. (2005). Probabilistic exposure assessment for
1837	children who contact CCA-treated playsets and decks using the stochastic human exposure and
1838	dose simulation model for the wood preservative exposure scenario (SHEDS-Wood).
1839	(NTIS/02937833). Washington, DC: U.S. Environmental Protection Agency.
1840	

# 1841 Appendix A ACUTE, CHRONIC, AND INTERMEDIATE DOSE RATE EQUATIONS

1843	The equations provided in this section were taken from the <u>CEM User Guide and associated appendices</u> .					
1844	A.1 Acute Dose Rate					
1845	Acute dose rate for inhalation of product used in an environment (CEM P_INH1 model), such as indoor,					
1846	butdoor, living room, garage, kitchen, bathroom, office, etc. was calculated as follows:					
1847						
1848	Equation_Apx A-1. Acute Dose Rate for Inhalation of Product Used in an Environment					
1849	$ADR = \frac{C_{air} \times Inh \times FQ \times D_{ac} \times ED}{BW \times AT \times CF_{1}}$					
10+7	$BW \times AT \times CF_1$					
1850	Where:					
1851	ADR = Acute Dose Rate (mg/kg-day)					
1852	$C_{air}$ = Concentration of DCHP in air (mg/m ³ )					
1853	Inh = Inhalation rate (m ³ /hr)					
1854	FQ = Frequency of product use (events/day)					
1855	$D_{ac}$ = Duration of use (min/event), acute					
1856	ED = Exposure duration (days of product usage)					
1857	BW = Body weight (kg)					
1858	AT = Averaging time (days)					
1859	$CF_1 = Conversion factor (60 min/hr)$					
1860						
1861	For the ADR calculations, an averaging time of 1 day is used. The airborne concentration in the above					
1862	equation is calculated using the high-end consumer product weight fraction, duration of use, and mass of					
1863	product used. Therefore, in this case, the ADR represents the maximum time-integrated dose over a 24-					
1864	hour period during the exposure event. CEM calculates ADRs for each possible 24-hour period over the					
1865	60-day modeling period ( <i>i.e.</i> , averaging of hours 1–24, 2–25, etc.) and then reports the highest of these					
1866	computed values as the ADR.					
1867	L					
1868	Acute dose rate for inhalation from article placed in environment (CEM A_INH1 model) was calculated					
1869	as follows, where the term environment refers to any indoor and outdoor location, such as garage,					
1870	kitchen, bathroom, living room, car interior, daycare, school room, office, backyard and so on:					
1871						
1872	Equation_Apx A-2. Acute Dose Rate for Inhalation from Article Placed in Environment					
	$C_{aas max} \times FracTime \times InhalAfter \times CF_1$					
1873	$ADR_{Air} = \frac{C_{gas_max} \times FracTime \times InhalAfter \times CF_{1}}{BW \times CF_{2}}$					
1874						
1875	Equation_Apx A-3. Acute Dose Rate for Particle Inhalation from Article Placed in Environment					
1075						
1876	$ADR_{Particulate} = \frac{DCHPRP_{air_max} \times RP_{air_avg} \times FracTime \times InhalAfter \times CF_{1}}{DW \times CF}$					
1077	$BW \times CF_2$					
1877						
1878	Equation_Apx A-4. Total Acute Dose Rate for Inhalation of Particulate and Air					
1879	$ADR_{total} = ADR_{Air} + ADR_{Particulate}$					
1880						
1881	Where:					
1882	$ADR_{Air}$ = Acute Dose Rate, air (mg/kg-day)					
1883	$ADR_{Particulate}$ = Acute Dose Rate, particulate (mg/kg-day)					

1884	ADR _{total}	= Acute Dose Rate, total (mg/kg-day)		
1885	$C_{gas_max}$	Maximum gas phase concentration ( $\mu g/m^3$ )		
1886	DCHPRP _{air_max}	= Maximum DCHP in respirable particle (RP) concentration, air		
1887	_	$(\mu g/mg)$		
1888	$RP_{air_max}$	= Maximum respirable particle concentration, air $(mg/m^3)$		
1889	FracTime	= Fraction of time in environment (unitless)		
1890	InhalAfter	= Inhalation rate after use $(m^3/hr)$		
1891	$CF_1$	= Conversion factor (24 hr/day)		
1892	$B\overline{W}$	= Body weight (kg)		
1893	$CF_2$	= Conversion factor $(1,000 \mu g/mg)$		
1894				
1895	Acute dose rate for ingestion	n after inhalation (CEM A_ING1 model) was calculated as follows:		
1896				
1897		Dose Rate from Ingestion after Inhalation		
1898	ADR _{IAI} [(DCHPRP × X RP × X IFm)	+ $(DCHPDust \cdot x Dust \cdot x IF_{r}) + (DCHPAhr \cdot x Ahr \cdot x IF_{r}) \times InholAfter x CF_{r}$		
1899	$=\frac{\left[\left(\frac{B^{2}}{B^{2}}\right)^{2}+1\right]}{\left(\frac{B^{2}}{B^{2}}\right)^{2}+1\right]}$	$+ (DCHPDust_{air_max} \times Dust_{air_max} \times IF_{Dust}) + (DCHPAbr_{air_max} \times Abr_{air_max} \times IF_{Abr})] \times InhalAfter \times CF_1$ BW × CF_2		
1900	Where:			
1900	ADR _{IAI}	= Acute Dose Rate from Ingestion and Inhalation (mg/kg-day)		
1902	DCHPRP _{air_max}	<ul> <li>Acute Dose Rate from ingestion and initiation (ing/kg-day)</li> <li>Maximum DCHP in respirable particles (RP) concentration, air</li> </ul>		
1902	Denn Krair_max	$(\mu g/mg)$		
1903 1904	RP _{air_max}	= Maximum RP concentration, air $(mg/m^3)$		
1904	IF air_max IF _{TSP}	<ul> <li>RP ingestion fraction (unitless)</li> </ul>		
1905	DCHPDust _{air_max}	= Maximum DCHP in dust concentration, air ( $\mu$ g/mg)		
1900 1907		= Maximum Defin m dust concentration, air (µg/mg) $= Maximum dust concentration, air (mg/m3)$		
1907	Dust _{air_max}	<ul> <li>Dust ingestion fraction (unitless)</li> </ul>		
1908	IF _{Dust} DCHPAbr _{air_avg}	<ul> <li>Dust ingestion fraction (unitiess)</li> <li>Maximum DCHP in abraded particle concentration, air (µg/mg)</li> </ul>		
1910	-			
	Abr _{air_avg}			
1911	IF _{Abr} In hal After	= Abraded particle ingestion fraction (unitless) Inhelation sets often use $(m^3/h^2)$		
1912	InhalAfter CE	= Inhalation rate after use $(m^3/hr)$		
1913	CF ₁	= Conversion factor (24 hr/day)		
1914 1915	BW	<ul> <li>Body weight (kg)</li> <li>Conversion factor (1,000 mg/g)</li> </ul>		
1915 1916	CF ₂	= Conversion factor $(1,000 \text{ mg/g})$		
1917	Acute daily dose rate for inc	estion of article mouthed (CEM A_ING2 model) was calculated as follows:		
1917	neme anny abservate for me	estion of unicle mouned (CENTA_11002 model) was calculated as follows.		
1919	Equation Apx A-6. Acute	Dose Rate for Ingestion of Article Mouthed		
		$MR \times CA \times D_m \times ED_{ac} \times CF_1$		
1920		$ADR = \frac{MR \times CA \times D_m \times ED_{ac} \times CF_1}{BW \times AT_{ac} \times CF_2}$		
1921	Where:			
1922		Dose Rate (mg/kg-day)		
1923	MR = Migration rate of chemical from article to saliva (mg/cm2/hr)			
1924	CA = Contact area of mouthing (cm2)			
1925	$D_m = Duration of mouthing (min/hr)$			
1926				
1927				
1928				
1929	$AT_{ac} = Averaging time, acute (days)$			
-	ut			

1930	$CF_2 =$	Conv	version factor (60 min/hr)		
1931					
1932	See Section 2.2.3.1 for migration rate inputs and determination of these values.				
1933					
1934	Acute dose rate for i	ncident	tal ingestion of dust (CEM A_ING3 model) was calculated as follows:		
1935					
1936			5 in CEM calculates DCHP concentration in small particles, termed		
1937			id large particles, termed dust, that are settled on the floor or surfaces. The		
1938	1		s bound to DCHP are available via incidental dust ingestion assuming a daily		
1939 1940	0		ction of the day that is spent in the zone with the DCHP-containing dust. The		
1940 1941	model uses a weight	eu uust	concentration, shown below.		
1942	Faustion Apy A.7	Acute	Dust Concentration		
	(RP _{floo}	$r_{max} \times D$	$CHPRP_{floor, max}) + (Dust_{floor, max} \times DCHPDust_{floor, max}) + (AbArt_{floor, max} \times DCHPAbArt_{floor, max})$		
1943	$Dust_{ac_wgt} = \frac{1}{2}$	max	$\frac{CHPRP_{floor_max}) + (Dust_{floor_max} \times DCHPDust_{floor_max}) + (AbArt_{floor_max} \times DCHPAbArt_{floor_max})}{(TSP_{floor_max} + Dust_{floor_max} + AbArt_{floor_max})}$		
1944	Where:				
1944			= Acute weighted dust concentration ( $\mu g/mg$ )		
1945	Dust _{ac_wgt}				
	RP _{floor_max}		= Maximum RP mass, floor (mg)		
1947	DCHPRP _{floo}	-	= Maximum DCHP in RP concentration, floor ( $\mu g/mg$ )		
1948	Dust _{floor_ma}		= Maximum dust mass, floor (mg)		
1949	DCHPDust _f				
1950	$AbArt_{floor_m}$	ıax	= Maximum abraded particles mass, floor (mg)		
1951	DCHPAbArt	_ floor_m	ax = Maximum floor dust DCHP concentration (µg/mg)		
1952					
1953	Equation_Apx A-8.	Acute	Dose Rate for Incidental Ingestion of Dust		
1954			$ADR = \frac{Dust_{ac_wgt} \times FracTime \times DustIng}{BW \times CF}$		
			$BW \times CF$		
1955	Where:				
1956	ADR	=	Acute Dose Rate (mg/kg-day)		
1957	$Dust_{ac_wgt}$	=	Acute weighted dust concentration (µg/mg)		
1958	FracTime	=	Fraction of time in environment (unitless)		
1959	DustIng	=	Dust ingestion rate (mg/day)		
1960	BW	=	Body weight (kg)		
1961	CF	=	Conversion factor (1,000 µg/mg)		
1962					
1963	-		e DCHP can volatilize from the DCHP-containing article to the air and then		
1964					
1965	the article. This is also estimated in A_ING3 model assuming the original DCHP concentration in the				
1966					
1967 1968	known or estimated as presented in E6. The model assumes partitioning behavior dominates, or instantaneous equilibrium is achieved. This is presented as a worst-case or upper bound scenario.				
1968	instantaneous equint		s achieved. This is presented as a worst-case of upper bound scenario.		
1909 1970	Equation Any A.9	Conce	entration of DCHP in Dust		
		Conce			
1971			$C_{d} = \frac{C_{0_art} \times K_{dust} \times CF}{K_{solid}}$		
1972			rsolid		
.//2					

1072	Wheney							
1973 1074	Where:							
1974 1075	$C_d = C_d$	Concentration of DCHP in dust (mg/mg) Initial DCHP concentration in article (mg/cm ³ )						
1975	$C_{0_art} =$	Initial DCHP concentration in article $(mg/cm^3)$						
1976	$K_{dust}$ = DCHP dust-air partition coefficient (m ³ /mg)							
1977	CF = Conversion factor (10 ⁶ cm ³ /m ³ )							
1978 1979	$K_{solid}$ = Solid air partition coefficient (unitless)							
1979	Once DCUP concer	tration in the dust is estimated, the acute dose rate can be calculated. The calculation						
1980		pper-end dust concentration.						
1981	Tenes on the same u	pper-end dust concentration.						
1983	Equation Apx A-1	0. Acute Dose Rate from Direct Transfer to Dust						
1984		$ADR_{DTD} = \frac{C_d \times FracTime \times DustIng}{BW}$						
1985	Where:							
1986	$ADR_{DTD}$	= Acute Dose Rate from direct transfer to dust (mg/kg-day)						
1987	$C_d$	= Concentration of DCHP in dust (mg/mg)						
1988	FracTime	= Fraction of time in environment (unitless)						
1989	DustIng	= Dust ingestion rate (mg/day)						
1990	BW	= Body weight (kg)						
1991								
1992	Acute dose rate for i	ingestion of product swallowed (CEM P_ING1 module) was calculated as follows:						
1993								
1994	Equation_Apx A-1	<b>1.</b> Acute Dose Rate for Ingestion of Product Swallowed by Mouthing $EQ \rightarrow M \rightarrow WE \rightarrow E_{L} \rightarrow CE \rightarrow ED$						
1995		$ADR = \frac{FQ_{ac} \times M \times WF \times F_{ing} \times CF_1 \times ED_{ac}}{BW \times AT_{ac}}$						
1006	Wheney	$BW \times AI_{ac}$						
1996	Where:	A sute Dess Data (ma/ka dav)						
1997	ADR = EQ	Acute Dose Rate (mg/kg-day)						
1998 1999	$FQ_{ac} = M =$	Frequency of use, acute (events/day) Mass of product used (g)						
2000	WF =	Weight fraction of chemical in product (unitless)						
2000	$F_{ing} =$	Fraction of product ingested (unitless)						
2001	<u>а п</u>	Conversion factor (1,000 mg/g)						
2002		Exposure duration, acute (days)						
2003	$ED_{ac} = AT_{ac} =$	Averaging time, acute (days)						
2004	BW =	Body weight (kg)						
2005	DW =	Dody weight (kg)						
2000	The model assumes	that the product is directly ingested as part of routine use, and the mass is dependent						
2007	on the weight fraction and use patterns associated with the product.							
		r martin restriction and restriction restrictions and restriction restrictions and restrict						
2009		ncer Chronic Dose						
2010	0	ily dose rate for inhalation of product used in an environment (CEM P_INH1						
2011	model) was calculate	ed as follows:						
2012								

# Equation_Apx A-12. Chronic Average Daily Dose Rate for Inhalation of Product Used in an Environment

2015 
$$CADD = \frac{C_{air} \times Inh \times FQ \times D_{cr} \times ED}{BW \times AT \times CF_1 \times CF_2}$$

2016

2017	Where:	
2018	CADD =	Chronic Average Daily Dose (mg/kg-day)
2019	$C_{air}$ =	Concentration of chemical in air (mg/m ³ )
2020	Inh =	Inhalation rate (m ³ /hr)
2021	FQ =	Frequency of use (events/year)
2022	$D_{cr}$ =	Duration of use (min/event), chronic
2023	ED =	Exposure duration (years of product usage)
2024	BW =	Body weight (kg)
2025	AT =	Averaging time (years)
2026	$CF_1 =$	Conversion factor (365 days/year)
2027	$CF_2 =$	Conversion factor (60 min/hr)
2028		

2029 CEM uses two defaults inhalation rates which trace to the Exposure Factors Handbook (see Table_Apx
2030 A-1 footnote), one when the person is using the product and another after the use has ended. Table_Apx
2031 A-1 shows the inhalation rates by receptor age category for during and after product use.

2032 2033

Age Group	Inhalation Rate During Use (m ³ /hr) ^a	Inhalation Rate After Use (m ³ /hr) ^b		
Adult ( $\geq$ 21 years)	0.74	0.61		
Youth (16–20 years)	0.72	0.68		
Youth (11–15 years)	0.78	0.63		
Child (6–10 years)	0.66	0.5		
Small Child (3–5 years)	0.66	0.42		
Infant (1–2 years)	0.72	0.35		
Infant (<1 year)	0.46	0.23		
^{<i>a</i>} Table 6-2, light intensity values (U.S. EPA, 2011a) ^{<i>b</i>} Table 6-1 (U.S. EPA, 2011a)				

## Table_Apx A-1. Inhalation Rates Used in CEM Product Models

2034

The inhalation dose is calculated iteratively at a 30-second interval during the first 24 hours and every hour after that for 60 days—taking into consideration the chemical emission rate over time, the volume of the house and each zone, the air exchange rate and interzonal airflow rate, and the exposed individual's locations and inhalation rates during and after product use.

2039

2040 *Chronic average daily dose rate for inhalation from article placed in environment* (CEM A_INH1
 2041 model) was calculated as follows:

2042

Equation_Apx A-13. Chronic Average Daily Dose Rate for Inhalation from Article Placed in
 Environment in Air

2045 
$$CADD_{Air} = \frac{C_{gas_avg} \times FracTime \times InhalAfter \times CF_1}{BW \times CF_2}$$

2046

2047 2048	Equation_Apx A-14. Chro Environment in Particula		erage Daily Dose Rate for Inhalation from Article Placed in		
2049			$\frac{RP_{air_avg} \times RP_{air_avg} \times (1 - IF_{RP})FracTime \times InhalAfter \times CF_1}{BW \times CF_2}$		
2049	CADD _{Particulate}		$BW \times CF_2$		
2050					
2051	Equation_Apx A-15. Tota	l Chroi	nic Average Daily Dose Rate for Inhalation of Particulate and Air		
2052	• – •		$DD_{total} = CADD_{Air} + CADD_{Particulate}$		
	<b>XX</b> 71				
2053	Where:		Character Deile Deers sin (mes (les deer)		
2054	CADD _{Air}	=	Chronic Average Daily Dose, air (mg/kg-day)		
2055	$CADD_{Particulate}$	=	Chronic Average Daily Dose, particulate (mg/kg-day)		
2056	$CADD_{total}$	=	Chronic Average Daily Dose, total (mg/kg-day)		
2057	$C_{gas_avg}$	=	Average gas phase concentration ( $\mu g/m^3$ )		
2058	$DCHPRP_{air_avg}$	=	Average DCHP in respirable particles (RP) concentration, air		
2059			(µg/mg)		
2060	$RP_{air_avg}$	=	Average RP concentration, air $(mg/m^3)$		
2061	$IF_{RP}$	=	RP ingestion fraction (unitless)		
2062	FracTime	=	Fraction of time in environment (unitless)		
2063	InhalAfter	=	Inhalation rate after use (m ³ /hr)		
2064	$CF_1$	=	Conversion factor (24 hr/day)		
2065	BW	=	Body weight (kg)		
2066	$CF_2$	=	Conversion factor $(1,000 \mu g/mg)$		
2067					
2068	Chronic average daily dose	rate fo	r ingestion after inhalation (CEM A_ING1 model) was calculated as		
2069					
2070					
2071	The CEM article model, E6, estimates DCHP concentrations in small and large airborne particles. While				
2072	these particles are expected to be inhaled, not all are able to penetrate the lungs and be trapped in the				
2073	upper airway and subsequently swallowed. The model estimates the mass of DCHP bound to airborne				
2074	small particles, respirable p	articles	(RP), and large particles ( <i>i.e.</i> , dust) that are inhaled and trapped in		
2075	the upper airway. The fract	ion that	is trapped in the airway is termed the ingestion fraction (IF). The		
2076	mass trapped is assumed to	be avai	lable for ingestion.		
2077					
2078	Equation_Apx A-16. Chro	onic Av	erage Daily Dose Rate from Ingestion after Inhalation		
2079					
2080	$CADD_{IAI}$				
2081	$=\frac{\left[\left(DCHPRP_{air_avg} \times RP_{air_{avg}} \times IF_{RP}\right)\right]}{\left[\left(DCHPRP_{air_avg} \times RP_{air_{avg}} \times IF_{RP}\right)\right]}$	) + (DCHF	$\frac{PDust_{air_avg} \times Dust_{air_{avg}} \times IF_{Dust}) + (DCHPAbr_{air_avg} \times Abr_{air_avg} \times IF_{Abr})] \times InhalAfter \times CF_{1}}{BW \times CF_{2}}$		
			$BW \times CF_2$		
2082	Where:				
2083	$CADD_{IAI}$	=	Chronic Average Daily Dose from ingestion after inhalation		
2084			(mg/kg-day)		
2085	$SVOCRP_{air_avg}$	=	Average DCHP in RP concentration, air (µg/mg)		
2086	RP _{air_avg}	=	Average RP concentration, air $(mg/m^3)$		
2087	IF _{RP}	=	RP ingestion fraction (unitless)		
2088	SVOCDust _{air_avg}	=	Average DCHP dust concentration, air (µg/mg)		
2089	Dust _{air_avg}	=	Average dust concentration, air $(mg/m^3)$		
2090	$IF_{Dust}$	=	Dust ingestion fraction (unitless)		
2090	SVOCAbr _{air_avg}	=	Average DCHP in abraded particle concentration, air (µg/mg)		
2071	5, 001101 air_avg	_	riverage Dern in abraded particle concentration, an (µg/mg)		

2092	$Abr_{air_avg}$ = Average abraded particle concentration, air (mg/m ³ )					
2093	$IF_{Abr}$ = Abraded particle ingestion fraction (unitless)					
2094	InhalAfter = Inhalation rate after use (m3/hr)					
2095	$CF_1$ = Conversion factor (24 hr/day)					
2095	BW = Body weight (kg)					
2090 2097						
	$CF_2$ = Conversion factor (1,000 mg/g)					
2098						
2099	Chronic average daily dose rate for ingestion of article mouthed (CEM A_ING2 model) was calculated					
2100	as follows:					
2101						
2102	The model assumes that a fraction of the chemical present in the article is ingested via object-to-mouth					
2103	contact or mouthing where the chemical of interest migrates from the article to the saliva. See Section					
2104	2.2.3.1 for migration rate inputs and determination of these values.					
2105						
2106	Equation_Apx A-17. Chronic Average Daily Dose Rate for Ingestion of Article Mouthed					
2107	$CADD = \frac{MR \times CA \times D_m \times ED_{cr} \times CF_1}{MR \times CA \times D_m \times ED_{cr} \times CF_1}$					
2107	$CADD = \frac{MR \times CA \times D_m \times ED_{cr} \times CF_1}{BW \times AT_{cr} \times CF_2}$					
2108	Where:					
2109	CADD = Chronic Average Daily Dose (mg/kg-day)					
2110	MR = Migration rate of chemical from article to saliva (mg/cm ² /hr)					
2111	CA = Contact area of mouthing (cm2)					
2112	$D_m$ = Duration of mouthing (min/hr)					
2113	$ED_{cr} = Exposure duration, chronic (years)$					
2113	$CF_1 = Conversion factor (24 hr/day)$					
2115	$AT_{cr} = $ Averaging time, chronic (years)					
2115	BW = Body weight (kg)					
2110	$CF_2 = Conversion factor (60 min/hr)$					
2117 2118	$Cr_2 = Conversion ractor (60 mm/m)$					
2118	Chronic average daily rate for incidental ingestion of dust (CEM A_ING3 model) was calculated as					
211)	follows:					
2120	Tonows.					
2121 2122	The article model in CEM E6 calculates DCHP concentration in small particles, termed respirable					
2122	particles (RP), and large particles, termed dust, that are settled on the floor or surfaces. The model					
2123	assumes these particles, bound to DCHP, are available via incidental dust ingestion assuming a daily					
2124	dust ingestion rate and a fraction of the day that is spent in the zone with the DCHP-containing dust. The					
2125						
2120	model uses a weighted dust concentration, shown below.					
2127 2128	Equation Any A 18 Chronic Dust Concentration					
2128	Equation_Apx A-18. Chronic Dust Concentration					
2130	Dust _{cr_wgt}					
0121	$(RP_{floor_avg} \times DCHPRP_{floor_avg}) + (Dust_{floor_avg} \times DCHPDust_{floor_avg}) + (AbArt_{floor_avg} \times DCHPAbArt_{floor_avg})$					
2131	$=\frac{\left(RP_{floor_avg} \times DCHPRP_{floor_avg}\right) + \left(Dust_{floor_avg} \times DCHPDust_{floor_avg}\right) + \left(AbArt_{floor_avg} \times DCHPAbArt_{floor_avg}\right)}{\left(RP_{floor_avg} + Dust_{floor_avg} + AbArt_{floor_avg}\right)}$					
2132	Where:					
2133	$Dust_{cr_wgt}$ = Chronic weighted dust concentration (µg/mg)					
2134	$RP_{floor_avg}$ = Average RP mass, floor (mg)					
2135	$DCHPRP_{floor_avg}$ = Average DCHP in RP concentration, floor (µg/mg)					
2136	$Dust_{floor_avg} = Average dust mass, floor (mg)$					
_100						

2137 2138	DCHPDust _{fl} AbArt _{floor_a}		$vg =$ Average DCHP in dust concentration, floor ( $\mu g/mg$ ) = Average abraded particles mass, floor (mg)
2139	DCHPAbArt	0	
2139		floor_	$avg = Average noor dust Dern concentration (\mu g/mg)$
2141	Equation_Apx A-19	9. Ch	ronic Average Daily Dose Rate for Incidental Ingestion of Dust
2142			$CADD = \frac{Dust_{cr_wgt} \times FracTime \times DustIng}{BW \times CF}$
2143	Where:		
2144	CADD	=	Chronic Average Daily Dose (mg/kg-day)
2145	Dust _{cr_w.gt}	=	Chronic weighted dust concentration (µg/mg)
2146	FracTime	=	Fraction of time in environment (unitless)
2147	DustIng	=	Dust ingestion rate (mg/day)
2148	BW	=	Body weight (kg)
2149	CF	=	Conversion factor $(1,000 \mu g/mg)$
2150			

The above equations assume DCHP can volatilize from the DCHP-containing article to the air and then partition to dust. Alternately, DCHP can partition directly from the article to dust in direct contact with the article. This is also estimated in the A_ING3 model assuming the original DCHP concentration in the article is known, and the density of the dust and dust-air and solid-air partitioning coefficients are either known or estimated as presented in the E6 CEM model. The model assumes partitioning behavior dominates, or instantaneous equilibrium is achieved. This is presented as a worst-case or upper bound scenario.

## 2158 A.3 Intermediate Average Daily Dose

The intermediate doses were calculated from the average daily dose, ADD, (µg/kg-day) CEM output for
that product using the same inputs summarized in Table 2-8 for inhalation and Table 2-9 for dermal.
EPA used professional judgment based on manufacturer and online product use descriptions to estimate
events per day and per month for the calculation of the intermediate dose:

### 2164 Equation_Apx A-20. Intermediate Average Daily Dose Equation

			$ADD \times Event per Month$
2165	In	termed	$liate Dose = \frac{1}{Events per Day}$
2166	Where:		
2167	Intermediate Dose	=	Intermediate average daily dose, µg/kg-month
2168	ADD	=	Average Daily Dose, µg/kg-day
2169	Event per Month	=	Events per month, month ⁻¹ , see Table_Apx A-2
2170	Event per Day	=	Events per day, day ⁻¹ , see Table_Apx A-2

#### 2171 2172

2163

## Table_Apx A-2. Short-Term Event per Month and Day Inputs

Product	Events Per Day ^a	Events Per Month ^a
Construction Adhesive for Small Scale Projects	3	4
Construction Sealant for Large Scale Projects	1	3
Lacquer Sealer (Non-Spray)	1	2
Lacquer Sealer (Spray)	1	2
^{<i>a</i>} Events per day and month values determined using professional judgement based on manufacturer product description use.		

2174	A.4 Dermal Absorption Dose N	Iodeling for Acute and Chronic Exposures	
2175	After calculating dermal absorption dose per event for each lifestage, chronic average daily dose, acute		
2176 2177	average daily dose, and intermediate average daily dose were calculated as described below.		
2178 2179	Acute dose rate for direct dermal contact with	product or article was calculated as follows:	
2180	Equation_Apx A-21. Acute Dose Rate for D	ermal per Event × Acute Frequency	
2181	$ADR_{Dermal} =$	Averaging Time	
2182			
2183			
2184	Dermai	se rate for dermal contact, mg/kg-day by body weight	
2185	L	of chemical absorbed per use, mg/kg by body weight	
2186	1 2	of exposure events per averaging period	
2187	0 0	eraging time, day ⁻¹	
2188			
2189	Chronic average daily dose rate for direct dermal contact with product or article was calculated as		
2190			
2191			
2192		y Dose Rate for Dermal	
2193	$CADD_{\text{Downsel}} = \frac{Dose}{d}$	ver Event × Chronic Frequency Averaging Time	
		Averaging Time	
2194			
2195			
2196	$CADD_{Dermal} = Chronic$	dermal rate for dermal contact, mg/kg-day by body	
2197	weight		
2198	Dose per Event = Amount	of chemical absorbed per use, mg/kg by body weight, and	
2199	<i>Chronic Frequency</i> = Number	of exposure events per averaging period	
2200	Averaging Time = Chronic	averaging time, day $^{-1}$	
2201			